EVI1‐mediated Programming of Normal and Malignant Hematopoiesis

Ecotropic viral integration site 1 (EVI1), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and malignant cells, most extensively studied in the context of hematopoiesis. EVI1 interacts with other transcription factors in a context‐dependent m...

Full description

Saved in:
Bibliographic Details
Published inHemaSphere Vol. 7; no. 10; pp. e959 - n/a
Main Authors Lux, Susanne, Milsom, Michael D.
Format Journal Article
LanguageEnglish
Published Philadelphia, PA Lippincott Williams & Wilkins 01.10.2023
Wiley
Subjects
Review
Online AccessGet full text
ISSN2572-9241
2572-9241
DOI10.1097/HS9.0000000000000959

Cover

Abstract Ecotropic viral integration site 1 (EVI1), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and malignant cells, most extensively studied in the context of hematopoiesis. EVI1 interacts with other transcription factors in a context‐dependent manner and regulates transcription and chromatin remodeling, thereby influencing the proliferation, differentiation, and survival of cells. Interestingly, it can act both as a transcriptional activator as well as a transcriptional repressor. EVI1 is expressed, and fulfills important functions, during the development of different tissues, including the nervous system and hematopoiesis, demonstrating a rigid spatial and temporal expression pattern. However, EVI1 is regularly overexpressed in a variety of cancer entities, including epithelial cancers such as ovarian and pancreatic cancer, as well as in hematologic malignancies like myeloid leukemias. Importantly, EVI1 overexpression is generally associated with a very poor clinical outcome and therapy‐resistance. Thus, EVI1 is an interesting candidate to study to improve the prognosis and treatment of high‐risk patients with “EVI1high” hematopoietic malignancies.
AbstractList Ecotropic viral integration site 1 (EVI1), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and malignant cells, most extensively studied in the context of hematopoiesis. EVI1 interacts with other transcription factors in a context-dependent manner and regulates transcription and chromatin remodeling, thereby influencing the proliferation, differentiation, and survival of cells. Interestingly, it can act both as a transcriptional activator as well as a transcriptional repressor. EVI1 is expressed, and fulfills important functions, during the development of different tissues, including the nervous system and hematopoiesis, demonstrating a rigid spatial and temporal expression pattern. However, EVI1 is regularly overexpressed in a variety of cancer entities, including epithelial cancers such as ovarian and pancreatic cancer, as well as in hematologic malignancies like myeloid leukemias. Importantly, EVI1 overexpression is generally associated with a very poor clinical outcome and therapy-resistance. Thus, EVI1 is an interesting candidate to study to improve the prognosis and treatment of high-risk patients with "EVI1high" hematopoietic malignancies.Ecotropic viral integration site 1 (EVI1), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and malignant cells, most extensively studied in the context of hematopoiesis. EVI1 interacts with other transcription factors in a context-dependent manner and regulates transcription and chromatin remodeling, thereby influencing the proliferation, differentiation, and survival of cells. Interestingly, it can act both as a transcriptional activator as well as a transcriptional repressor. EVI1 is expressed, and fulfills important functions, during the development of different tissues, including the nervous system and hematopoiesis, demonstrating a rigid spatial and temporal expression pattern. However, EVI1 is regularly overexpressed in a variety of cancer entities, including epithelial cancers such as ovarian and pancreatic cancer, as well as in hematologic malignancies like myeloid leukemias. Importantly, EVI1 overexpression is generally associated with a very poor clinical outcome and therapy-resistance. Thus, EVI1 is an interesting candidate to study to improve the prognosis and treatment of high-risk patients with "EVI1high" hematopoietic malignancies.
Ecotropic viral integration site 1 (EVI1 ), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and malignant cells, most extensively studied in the context of hematopoiesis. EVI1 interacts with other transcription factors in a context-dependent manner and regulates transcription and chromatin remodeling, thereby influencing the proliferation, differentiation, and survival of cells. Interestingly, it can act both as a transcriptional activator as well as a transcriptional repressor. EVI1 is expressed, and fulfills important functions, during the development of different tissues, including the nervous system and hematopoiesis, demonstrating a rigid spatial and temporal expression pattern. However, EVI1 is regularly overexpressed in a variety of cancer entities, including epithelial cancers such as ovarian and pancreatic cancer, as well as in hematologic malignancies like myeloid leukemias. Importantly, EVI1 overexpression is generally associated with a very poor clinical outcome and therapy-resistance. Thus, EVI1 is an interesting candidate to study to improve the prognosis and treatment of high-risk patients with “EVI1 high ” hematopoietic malignancies.
Ecotropic viral integration site 1 (EVI1), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and malignant cells, most extensively studied in the context of hematopoiesis. EVI1 interacts with other transcription factors in a context‐dependent manner and regulates transcription and chromatin remodeling, thereby influencing the proliferation, differentiation, and survival of cells. Interestingly, it can act both as a transcriptional activator as well as a transcriptional repressor. EVI1 is expressed, and fulfills important functions, during the development of different tissues, including the nervous system and hematopoiesis, demonstrating a rigid spatial and temporal expression pattern. However, EVI1 is regularly overexpressed in a variety of cancer entities, including epithelial cancers such as ovarian and pancreatic cancer, as well as in hematologic malignancies like myeloid leukemias. Importantly, EVI1 overexpression is generally associated with a very poor clinical outcome and therapy‐resistance. Thus, EVI1 is an interesting candidate to study to improve the prognosis and treatment of high‐risk patients with “EVI1high” hematopoietic malignancies.
Ecotropic viral integration site 1 (EVI1), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and malignant cells, most extensively studied in the context of hematopoiesis. EVI1 interacts with other transcription factors in a context-dependent manner and regulates transcription and chromatin remodeling, thereby influencing the proliferation, differentiation, and survival of cells. Interestingly, it can act both as a transcriptional activator as well as a transcriptional repressor. EVI1 is expressed, and fulfills important functions, during the development of different tissues, including the nervous system and hematopoiesis, demonstrating a rigid spatial and temporal expression pattern. However, EVI1 is regularly overexpressed in a variety of cancer entities, including epithelial cancers such as ovarian and pancreatic cancer, as well as in hematologic malignancies like myeloid leukemias. Importantly, EVI1 overexpression is generally associated with a very poor clinical outcome and therapy-resistance. Thus, EVI1 is an interesting candidate to study to improve the prognosis and treatment of high-risk patients with “EVI1high” hematopoietic malignancies.
Author Lux, Susanne
Milsom, Michael D.
Author_xml – sequence: 1
  givenname: Susanne
  surname: Lux
  fullname: Lux, Susanne
  organization: German Cancer Research Center (DKFZ)
– sequence: 2
  givenname: Michael D.
  orcidid: 0000-0002-3567-254X
  surname: Milsom
  fullname: Milsom, Michael D.
  email: michael.milsom@dkfz.de
  organization: DKFZ‐ZMBH Alliance
BookMark eNqNkctu1DAUhiNUJErpG7DIks0UX2MbCaFSTZmRWkDisrVs5yTj4sSD7aHqro_QZ-RJSJkRarsp3tjyOd_nY_3Pq70xjlBVLzE6wkiJ14sv6gjdXYqrJ9U-4YLMFGF47875WXWY88XUg5VSDRH71fH8-xL_vr4ZoPWmQFt_TrFPZhj82Nexqz_GNJhQm7Gtz03w_WjGUi9gMCWuo4fs84vqaWdChsPdflB9O51_PVnMzj59WJ4cn80c51zNOoqos5hhSx0w4AJ1opPSuM5hoRRusXSEgmyEtMiatnFKIZiKHWGtlZYeVMutt43mQq-TH0y60tF4_fcipl6bVLwLoAU43jHbCtEyZgVWDUK2sa0FijilbHK927rWGzv93MFYkgn3pPcro1_pPv7SGHFOMZGT4dXOkOLPDeSiB58dhGBGiJusiRRM0oY1ZGpl21aXYs4Jun_vYKRvI9RThPphhBP25gHmfDHFx9uJfHgMllv4MoYCKf8Im0tIegUmlNVj6Nsd6gNc_desejE_p-9PEZnCo38ANNfFvA
CitedBy_id crossref_primary_10_1016_j_neurot_2024_e00443
crossref_primary_10_3389_fonc_2024_1400461
crossref_primary_10_1016_j_canlet_2025_217547
Cites_doi 10.1016/j.ccr.2014.02.008
10.1007/s00277-003-0778-y
10.1038/27945
10.1097/HS9.0000000000000471
10.1074/jbc.M414305200
10.1200/JCO.2011.41.5505
10.1038/sj.leu.2403346
10.1093/emboj/19.12.2958
10.1371/journal.pone.0089397
10.1038/onc.2012.222
10.1002/mc.21852
10.1126/scitranslmed.aao3003
10.1182/blood-2011-03-343897
10.1038/bcj.2013.76
10.1093/nar/gkt1036
10.1016/j.cancergen.2011.06.002
10.1038/s41375-018-0291-x
10.1038/sj.leu.2401360
10.3324/haematol.2021.276048
10.1038/s41586-022-05203-0
10.1038/onc.2013.204
10.1182/blood.2021015325
10.1182/blood-2010-01-264234
10.1128/MCB.00363-06
10.1038/s41467-021-25862-3
10.1158/0008-5472.CAN-08-2562
10.1038/sj.leu.2404281
10.1182/blood.V70.5.1338.1338
10.1016/j.cell.2014.02.019
10.1182/blood.2022016592
10.1038/onc.2009.288
10.1038/ng.3488
10.1016/S0021-9258(19)51041-9
10.1074/jbc.M106733200
10.15283/ijsc18021
10.1073/pnas.1119229109
10.1111/bjh.13898
10.1002/gcc.21992
10.1038/nm.2088
10.1073/pnas.1309310110
10.1002/gcc.20532
10.1016/j.ccell.2017.02.017
10.1182/blood.V97.9.2815
10.1126/science.1105063
10.1182/blood-2007-10-119230
10.3324/haematol.2019.241885
10.1038/s41467-018-06208-y
10.1182/blood-2010-04-281337
10.3324/haematol.13192
10.1038/onc.2010.510
10.1186/s13073-020-00724-7
10.1182/blood.V68.3.652.652
10.1016/j.cell.2013.03.036
10.1182/blood-2002-10-3243
10.1182/blood-2015-07-653840
10.1038/leu.2008.118
10.1038/leu.2012.211
10.1038/s41375-021-01235-z
10.1038/sj.leu.2401585
10.1093/nar/gky1192
10.1007/s40487-019-0095-9
10.1038/onc.2016.325
10.1200/JCO.2009.26.0646
10.1038/onc.2014.108
10.1182/blood.V84.4.1243.1243
10.1158/0008-5472.CAN-06-3962
10.1016/j.bcmd.2007.07.012
10.1158/2159-8290.CD-19-1469
10.1182/blood-2009-07-234310
10.1038/s41586-022-04571-x
10.1016/j.celrep.2017.05.005
10.1186/1471-2407-9-368
10.1038/leu.2009.202
10.1182/blood.2019003701
10.1182/blood-2016-03-643544
10.1371/journal.pone.0020793
10.1182/bloodadvances.2022008018
10.3324/haematol.2011.040535
10.1111/bjh.12444
10.1182/blood-2010-09-308726
10.1038/sj.leu.2400584
10.1309/AJCP7W9VMJENZOVG
10.1158/0008-5472.CAN-06-2366
10.1038/sj.leu.2404020
10.1016/S0925-4773(97)00057-9
10.1182/bloodadvances.2018016501
10.1038/nm.4283
10.1182/blood-2017-09-806489
10.1182/blood.V76.12.2594.2594
10.1126/science.1186624
10.1038/s41419-020-03099-0
10.1016/j.cell.2013.03.035
10.1016/j.stem.2008.06.002
10.5966/sctm.2012-0109
10.1038/leu.2012.363
10.1182/blood-2002-05-1459
10.1016/S0092-8674(88)91175-0
10.1038/sj.emboj.7600679
10.1084/jem.20110447
10.1038/s41590-022-01370-4
10.1182/blood-2016-12-756767
10.1016/j.ajhg.2015.10.010
10.1038/ng.913
10.1007/s00277-012-1457-7
10.1038/leu.2012.355
10.1200/JCO.2010.29.2771
10.1038/leu.2010.47
10.1182/blood-2009-12-261602
10.1182/blood.2022015850
10.1182/blood-2013-03-490425
10.1038/s41375-022-01734-7
ContentType Journal Article
Copyright Copyright © 2023 The Author(s).
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. 2023
Copyright_xml – notice: Copyright © 2023 The Author(s).
– notice: Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
– notice: Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. 2023
DBID 24P
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1097/HS9.0000000000000959
DatabaseName Wiley Online Library Open Access
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
EISSN 2572-9241
EndPage n/a
ExternalDocumentID oai_doaj_org_article_7ec5f4bd77d44b719600b6bdbe305334
PMC10553128
10_1097_HS9_0000000000000959
HemaSphere-2022-0073
HEM3BF02678
Genre reviewArticle
review-article
GrantInformation_xml – fundername: Dietmar Hopp Stiftung (MDM)
– fundername: DKFZ Postdoctoral Fellowship Program (SL)
GroupedDBID 0R~
24P
53G
AAAAV
AAHPQ
AASCR
ABASU
ABDIG
ABVCZ
ACCMX
ACGFS
ACILI
ADBBV
ADHPY
ADPDF
AFDTB
AFKRA
AHVBC
AINUH
AJIOK
AJNWD
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
BCNDV
BENPR
BQLVK
CCPQU
DIWNM
EBS
EEVPB
FCALG
GNXGY
GQDEL
GROUPED_DOAJ
HLJTE
HYE
IKREB
OK1
OPUJH
OVD
OVDNE
OVEED
OXXIT
PIMPY
RLZ
RPM
TEORI
TSPGW
AAYXX
CITATION
M~E
PHGZM
PHGZT
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
WIN
5PM
ID FETCH-LOGICAL-c5559-f303cb141b3ce4e570f7f88acfc17991d18c23e8678b0bad6c990efc1f24db8b3
IEDL.DBID DOA
ISSN 2572-9241
IngestDate Wed Aug 27 01:28:03 EDT 2025
Thu Aug 21 18:35:50 EDT 2025
Thu Sep 04 16:41:41 EDT 2025
Tue Jul 01 03:04:39 EDT 2025
Thu Apr 24 23:04:54 EDT 2025
Wed Apr 16 02:18:43 EDT 2025
Wed Jan 22 16:15:24 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License Attribution
http://creativecommons.org/licenses/by/4.0
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5559-f303cb141b3ce4e570f7f88acfc17991d18c23e8678b0bad6c990efc1f24db8b3
Notes Received: May 2, 2022 / Accepted: August 14, 2023 Correspondence: Michael D. Milsom (michael.milsom@dkfz.de).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-3567-254X
OpenAccessLink https://doaj.org/article/7ec5f4bd77d44b719600b6bdbe305334
PQID 2874836462
PQPubID 23479
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_7ec5f4bd77d44b719600b6bdbe305334
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10553128
proquest_miscellaneous_2874836462
crossref_primary_10_1097_HS9_0000000000000959
crossref_citationtrail_10_1097_HS9_0000000000000959
wolterskluwer_health_10_1097_HS9_0000000000000959
wiley_primary_10_1097_HS9_0000000000000959_HEM3BF02678
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate October 2023
PublicationDateYYYYMMDD 2023-10-01
PublicationDate_xml – month: 10
  year: 2023
  text: October 2023
PublicationDecade 2020
PublicationPlace Philadelphia, PA
PublicationPlace_xml – name: Philadelphia, PA
PublicationTitle HemaSphere
PublicationYear 2023
Publisher Lippincott Williams & Wilkins
Wiley
Publisher_xml – name: Lippincott Williams & Wilkins
– name: Wiley
References 2010; 16
2011; 117
2013; 2
2013; 122
2014; 25
2020; 12
2020; 11
2020; 10
1998; 394
2018; 9
2018; 2
2000; 19
2006; 20
2010; 24
1994; 269
2010; 116
2010; 28
1997; 57
2013; 52
2006; 26
2022; 609
2022; 36
2008; 22
2013; 110
2022; 604
2008; 111
2007; 67
2016; 48
1995; 9
2019; 7
2009; 69
2010; 327
2019; 33
2017; 130
2011; 6
1996; 10
1994; 84
2012; 109
2014; 157
2014; 42
2001; 276
2019; 47
2008; 47
2008; 40
2018; 11
2018; 10
2003; 101
2014; 33
1990; 5
2016; 172
2013; 27
2023; 141
2023; 7
1987; 70
2011; 96
2013; 162
2008; 3
2005; 24
2012; 51
2018; 131
2011; 204
2021; 35
2017; 31
2011; 208
2023; 24
2020; 4
2014; 4
1997; 11
2017; 36
1999; 13
2005; 308
2020; 136
2013; 153
2014; 9
2001; 97
1990; 76
2004; 83
1997; 65
2015; 97
2021; 106
1995; 10
2017; 23
1988; 54
2011; 30
2020; 107
2016; 127
2008; 93
2009; 28
1993; 13
2005; 280
2012; 91
2022; 140
2021; 12
2004; 18
2013; 32
1986; 68
2013; 31
1988; 8
2010; 133
2009; 9
2011; 43
2017; 19
Lugthart, van Drunen, van Norden (R25) 2008; 111
Groeschel, Schlenk, Engelmann (R30) 2013; 31
Huber, Haferlach, Meggendorfer (R81) 2022; 36
Chacon, Beck, Perera (R87) 2014; 42
Tanaka, Nishida, Mitani (R64) 1994; 269
Kurokawa, Mitani, Irie (R56) 1998; 394
Stevens, Hanson, De Leonibus (R42) 2014; 4
Dreyfus, Bouscary, Melle (R35) 1995; 9
Lugthart, Figueroa, Bindels (R61) 2011; 117
Arber, Orazi, Hasserjian (R28) 2016; 127
Ho, Alonzo, Gerbing (R29) 2013; 162
Kang, Kim, Kim (R114) 2018; 11
Balgobind, Lugthart, Hollink (R33) 2010; 24
Rubin, Larson, Bitter (R69) 1987; 70
Whyte, Orlando, Hnisz (R111) 2013; 153
Laricchia-Robbio, Nucifora (R17) 2008; 40
Trubia, Albano, Cavazzini (R93) 2006; 20
Masamoto, Chiba, Mizuno (R51) 2023; 7
Wang, Krivtsov, Sinha (R105) 2010; 327
Vázquez, Maicas, Cervera (R27) 2011; 96
Morishita, Parganas, Bartholomew (R2) 1990; 5
Morishita, Parker, Mucenski (R101) 1988; 54
Paquette, Nicoll, Chalukya (R39) 2011; 204
Meyer, Bristow, Wappett (R94) 2011; 117
Sood, Talwar-Trikha, Chakrabarti (R6) 1999; 13
Ottema, Mulet-Lazaro, Beverloo (R85) 2020; 136
Kiehlmeier, Rafiee, Bakr (R112) 2021; 35
Storlazzi, Anelli, Albano (R86) 2004; 83
Laricchia-Robbio, Premanand, Rinaldi (R62) 2009; 69
Yamazaki, Suzuki, Otsuki (R78) 2014; 25
Quentin, Cuccuini, Ceccaldi (R95) 2011; 117
Ogawa, Kurokawa, Tanaka (R37) 1996; 10
Bluteau, Sebert, Leblanc (R22) 2018; 131
Laricchia-Robbio, Fazzina, Li (R63) 2006; 26
Konantz, Andre, Ebinger (R41) 2013; 27
Goyama, Yamamoto, Shimabe (R18) 2008; 3
Carvajal, Neriah, Senecal (R118) 2018; 10
Bard-Chapeau, Szumska, Jacob (R12) 2014; 9
Queisser, Hagedorn, Wang (R48) 2017; 36
Senyuk, Premanand, Xu (R60) 2011; 6
Barjesteh van Waalwijk van Doorn-Khosrovani, Erpelinck, van Putten (R31) 2003; 101
Verhagen, Smit, Rutten (R113) 2016; 127
Ayoub, Wilson, McGrath (R49) 2018; 9
Ivanochko, Halabelian, Henderson (R7) 2019; 47
Yuasa, Oike, Iwama (R13) 2005; 24
Schmoellerl, Barbosa, Minnich (R50) 2023; 141
Paredes, Kelly, Geary (R10) 2020; 11
Benajiba, Alexe, Su (R66) 2019; 33
Deng, Cao, Liu (R47) 2013; 52
Soderholm, Kobayashi, Mathieu (R4) 1997; 11
Chakraborty, Senyuk, Sitailo (R58) 2001; 276
Österberg, Levan, Partheen (R44) 2009; 9
Maki, Yamagata, Yamazaki (R71) 2006; 20
De Weer, Speleman, Cauwelier (R91) 2008; 93
Peeters, Wlodarska, Baens (R74) 1997; 57
Tönnies, Huber, Kühl (R97) 2003; 101
Alliston, Ko, Cao (R57) 2005; 280
Sato, Goyama, Kataoka (R40) 2014; 33
Haas, Kundi, Sperr (R24) 2008; 47
Hoyt, Bartholomew, Davis (R11) 1997; 65
Kurokawa, Mitani, Yamagata (R67) 2000; 19
Paubelle, Plesa, Hayette (R115) 2019; 7
Hahn, Chong, Carmichael (R80) 2011; 43
Tanaka, Nakano, Nomura (R82) 2022; 140
Nanjundan, Nakayama, Cheng (R43) 2007; 67
Senyuk, Sinha, Li (R65) 2007; 67
Krivtsov, Figueroa, Sinha (R106) 2013; 27
Sitailo, Sood, Barton (R5) 1999; 13
Yoshimi, Goyama, Watanabe-Okochi (R54) 2011; 117
Wang, Qiao, Asangani (R117) 2017; 31
Kustikova, Schwarzer, Stahlhut (R23) 2013; 27
Maicas, Vázquez, Vicente (R98) 2013; 32
Tanaka, Suzuki, Shibahara (R46) 2014; 33
Germeshausen, Ancliff, Estrada (R20) 2018; 2
Stevens-Kroef, Poppe, van Zelderen-Bhola (R92) 2004; 18
Grasedieck, Cabantog, MacPhee (R90) 2020; 107
Bard-Chapeau, Gunaratne, Kumar (R9) 2013; 110
Thol, Yun, Sonntag (R36) 2012; 91
Rubin, Larson, Anastasi (R70) 1990; 76
Wierzbinska, Toth, Ishaque (R108) 2020; 12
Kustikova, Fehse, Modlich (R103) 2005; 308
Lugthart, Groschel, Beverloo (R32) 2010; 28
Lovén, Hoke, Lin (R110) 2013; 153
Arai, Yoshimi, Shimabe (R99) 2011; 117
Izutsu, Kurokawa, Imai (R55) 2001; 97
Oakes, Seifert, Assenov (R109) 2016; 48
Cioc, Wagner, MacMillan (R96) 2010; 133
Delwel, Funabiki, Kreider (R1) 1993; 13
Daghistani, Marin, Khorashad (R38) 2010; 116
Arber, Orazi, Hasserjian (R75) 2022; 140
Mucenski, Taylor, Ihle (R100) 1988; 8
Patel, Appaiah, Burnett (R45) 2011; 30
Kellaway, Keane, Kennett (R73) 2021; 106
Beck, Thoms, Perera (R84) 2013; 122
Modlich, Schambach, Brugman (R102) 2008; 22
Bard-Chapeau, Jeyakani, Kok (R53) 2012; 109
Goyama, Nitta, Yoshino (R59) 2010; 24
Katayama, Suzuki, Yamaoka (R79) 2017; 130
Morishita, Suzukawa, Taki (R3) 1995; 10
Voit, Tao, Yu (R19) 2023; 24
Niihori, Ouchi-Uchiyama, Sasahara (R21) 2015; 97
Pandolfi, Barreyro, Steidl (R107) 2013; 2
Groeschel, Lugthart, Schlenk (R26) 2010; 28
Cai, Chu, Goldberg (R68) 2020; 10
Russell, List, Greenberg (R34) 1994; 84
Yokomizo, Ideue, Morino-Koga (R15) 2022; 609
Stein, Ott, Schultze-Strasser (R104) 2010; 16
Loke, Assi, Imperato (R72) 2017; 19
Shimabe, Goyama, Watanabe-Okochi (R52) 2009; 28
Fenouille, Bassil, Ben-Sahra (R116) 2017; 23
Gröschel, Sanders, Hoogenboezem (R77) 2014; 157
D'Angiò, Fazio, Grioni (R89) 2020; 4
Hinai, Valk (R8) 2016; 172
Ottema, Mulet-Lazaro, Erpelinck-Verschueren (R83) 2021; 12
Kataoka, Sato, Yoshimi (R14) 2011; 208
Bernstein, Bagg, Pinto (R76) 1986; 68
Calvanese, Capellera-Garcia, Ma (R16) 2022; 604
Haferlach, Bacher, Grossmann (R88) 2012; 51
Niihori (R21-20231004) 2015; 97
Kang (R114-20231004) 2018; 11
Paredes (R10-20231004) 2020; 11
Haferlach (R88-20231004) 2012; 51
Kataoka (R14-20231004) 2011; 208
Huber (R81-20231004) 2022; 36
Trubia (R93-20231004) 2006; 20
D’Angiò (R89-20231004) 2020; 4
Stevens-Kroef (R92-20231004) 2004; 18
Tanaka (R64-20231004) 1994; 269
Lugthart (R61-20231004) 2011; 117
Kellaway (R73-20231004) 2021; 106
Meyer (R94-20231004) 2011; 117
Cioc (R96-20231004) 2010; 133
Bluteau (R22-20231004) 2018; 131
Laricchia-Robbio (R62-20231004) 2009; 69
Yamazaki (R78-20231004) 2014; 25
Schmoellerl (R50-20231004) 2023; 141
Senyuk (R65-20231004) 2007; 67
Whyte (R111-20231004) 2013; 153
Senyuk (R60-20231004) 2011; 6
Hoyt (R11-20231004) 1997; 65
Benajiba (R66-20231004) 2019; 33
Stein (R104-20231004) 2010; 16
Sitailo (R5-20231004) 1999; 13
Ivanochko (R7-20231004) 2019; 47
Lugthart (R32-20231004) 2010; 28
Masamoto (R51-20231004) 2023; 7
Arber (R28-20231004) 2016; 127
Ottema (R83-20231004) 2021; 12
Tanaka (R82-20231004) 2022; 140
Loke (R72-20231004) 2017; 19
Morishita (R2-20231004) 1990; 5
Kurokawa (R56-20231004) 1998; 394
Carvajal (R118-20231004) 2018; 10
Russell (R34-20231004) 1994; 84
Fenouille (R116-20231004) 2017; 23
Queisser (R48-20231004) 2017; 36
Ogawa (R37-20231004) 1996; 10
Rubin (R70-20231004) 1990; 76
Soderholm (R4-20231004) 1997; 11
Grasedieck (R90-20231004) 2020; 107
Tanaka (R46-20231004) 2014; 33
Groeschel (R30-20231004) 2013; 31
Barjesteh van Waalwijk van Doorn-Khosrovani (R31-20231004) 2003; 101
Kustikova (R103-20231004) 2005; 308
Paquette (R39-20231004) 2011; 204
Patel (R45-20231004) 2011; 30
Vázquez (R27-20231004) 2011; 96
Österberg (R44-20231004) 2009; 9
Kiehlmeier (R112-20231004) 2021; 35
Dreyfus (R35-20231004) 1995; 9
Groeschel (R26-20231004) 2010; 28
Lovén (R110-20231004) 2013; 153
Yokomizo (R15-20231004) 2022; 609
Lugthart (R25-20231004) 2008; 111
Maicas (R98-20231004) 2013; 32
Beck (R84-20231004) 2013; 122
Sood (R6-20231004) 1999; 13
Laricchia-Robbio (R63-20231004) 2006; 26
Goyama (R18-20231004) 2008; 3
Cai (R68-20231004) 2020; 10
Delwel (R1-20231004) 1993; 13
Morishita (R101-20231004) 1988; 54
Bernstein (R76-20231004) 1986; 68
Bard-Chapeau (R9-20231004) 2013; 110
Mucenski (R100-20231004) 1988; 8
Bard-Chapeau (R53-20231004) 2012; 109
Arai (R99-20231004) 2011; 117
Morishita (R3-20231004) 1995; 10
Izutsu (R55-20231004) 2001; 97
Deng (R47-20231004) 2013; 52
Krivtsov (R106-20231004) 2013; 27
Laricchia-Robbio (R17-20231004) 2008; 40
Arber (R75-20231004) 2022; 140
Hinai (R8-20231004) 2016; 172
Balgobind (R33-20231004) 2010; 24
Wang (R105-20231004) 2010; 327
Ho (R29-20231004) 2013; 162
Katayama (R79-20231004) 2017; 130
Verhagen (R113-20231004) 2016; 127
Chakraborty (R58-20231004) 2001; 276
Modlich (R102-20231004) 2008; 22
Wierzbinska (R108-20231004) 2020; 12
Thol (R36-20231004) 2012; 91
De Weer (R91-20231004) 2008; 93
Peeters (R74-20231004) 1997; 57
Daghistani (R38-20231004) 2010; 116
Konantz (R41-20231004) 2013; 27
Gröschel (R77-20231004) 2014; 157
Yoshimi (R54-20231004) 2011; 117
Rubin (R69-20231004) 1987; 70
Pandolfi (R107-20231004) 2013; 2
Quentin (R95-20231004) 2011; 117
Ayoub (R49-20231004) 2018; 9
Voit (R19-20231004) 2023; 24
Maki (R71-20231004) 2006; 20
Wang (R117-20231004) 2017; 31
Shimabe (R52-20231004) 2009; 28
Calvanese (R16-20231004) 2022; 604
Stevens (R42-20231004) 2014; 4
Ottema (R85-20231004) 2020; 136
Bard-Chapeau (R12-20231004) 2014; 9
Haas (R24-20231004) 2008; 47
Yuasa (R13-20231004) 2005; 24
Storlazzi (R86-20231004) 2004; 83
Kurokawa (R67-20231004) 2000; 19
Paubelle (R115-20231004) 2019; 7
Sato (R40-20231004) 2014; 33
Chacon (R87-20231004) 2014; 42
Oakes (R109-20231004) 2016; 48
Germeshausen (R20-20231004) 2018; 2
Kustikova (R23-20231004) 2013; 27
Hahn (R80-20231004) 2011; 43
Nanjundan (R43-20231004) 2007; 67
Goyama (R59-20231004) 2010; 24
Tönnies (R97-20231004) 2003; 101
Alliston (R57-20231004) 2005; 280
References_xml – volume: 101
  start-page: 837
  year: 2003
  end-page: 845
  article-title: High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients
  publication-title: Blood
– volume: 52
  start-page: 255
  year: 2013
  end-page: 264
  article-title: Overexpression of Evi‐1 oncoprotein represses TGF‐β signaling in colorectal cancer
  publication-title: Mol Carcinog
– volume: 27
  start-page: 56
  year: 2013
  end-page: 65
  article-title: EVI‐1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia
  publication-title: Leukemia
– volume: 133
  start-page: 92
  year: 2010
  end-page: 100
  article-title: Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with Fanconi anemia: morphologic and cytogenetic characteristics
  publication-title: Am J Clin Pathol
– volume: 10
  start-page: eaao3003
  year: 2018
  article-title: Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
  publication-title: Sci Transl Med
– volume: 110
  start-page: E2885
  year: 2013
  end-page: E2894
  article-title: EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation
  publication-title: Proc Natl Acad Sci USA
– volume: 23
  start-page: 301
  year: 2017
  end-page: 313
  article-title: The creatine kinase pathway is a metabolic vulnerability in EVI1‐positive acute myeloid leukemia
  publication-title: Nat Med
– volume: 604
  start-page: 534
  year: 2022
  end-page: 540
  article-title: Mapping human haematopoietic stem cells from haemogenic endothelium to birth
  publication-title: Nature
– volume: 204
  start-page: 392
  year: 2011
  end-page: 397
  article-title: Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors
  publication-title: Cancer Genet
– volume: 117
  start-page: 6304
  year: 2011
  end-page: 6314
  article-title: Evi‐1 is a transcriptional target of mixed‐lineage leukemia oncoproteins in hematopoietic stem cells
  publication-title: Blood
– volume: 24
  start-page: 81
  year: 2010
  end-page: 88
  article-title: EVI‐1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization
  publication-title: Leukemia
– volume: 12
  start-page: 1
  year: 2020
  end-page: 19
  article-title: Methylome‐based cell‐of‐origin modeling (Methyl‐COOM) identifies aberrant expression of immune regulatory molecules in CLL
  publication-title: Genome Med
– volume: 65
  start-page: 55
  year: 1997
  end-page: 70
  article-title: The Evil proto‐oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development
  publication-title: Mech Dev
– volume: 7
  start-page: 121
  year: 2019
  end-page: 130
  article-title: Efficacy of All‐Trans‐Retinoic Acid in high‐risk acute myeloid leukemia with overexpression of EVI1
  publication-title: Oncol Ther
– volume: 42
  start-page: D172
  issue: D1
  year: 2014
  end-page: D177
  article-title: BloodChIP: a database of comparative genome‐wide transcription factor binding profiles in human blood cells
  publication-title: Nucleic Acids Res
– volume: 35
  start-page: 3127
  year: 2021
  end-page: 3138
  article-title: Identification of therapeutic targets of the hijacked super‐enhancer complex in EVI1‐rearranged leukemia
  publication-title: Leukemia
– volume: 84
  start-page: 1243
  year: 1994
  end-page: 1248
  article-title: Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations
  publication-title: Blood
– volume: 47
  start-page: 1225
  year: 2019
  end-page: 1238
  article-title: Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex
  publication-title: Nucleic Acids Res
– volume: 10
  start-page: 1500
  year: 2020
  end-page: 1513
  article-title: Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition
  publication-title: Cancer Discov
– volume: 136
  start-page: 224
  year: 2020
  end-page: 234
  article-title: Atypical 3q26/MECOM rearrangements genocopy inv (3)/t (3; 3) in acute myeloid leukemia
  publication-title: Blood
– volume: 117
  start-page: 6047
  year: 2011
  end-page: 6050
  article-title: Fanconi anemia (FA)–associated 3q gains in leukemic transformation consistently target EVI1, but do not affect low TERC expression in FA
  publication-title: Blood
– volume: 127
  start-page: 2391
  year: 2016
  end-page: 2405
  article-title: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
  publication-title: Blood
– volume: 24
  start-page: 1976
  year: 2005
  end-page: 1987
  article-title: Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA‐2 expression
  publication-title: EMBO J
– volume: 36
  start-page: 2927
  year: 2022
  end-page: 2930
  article-title: SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre‐phase
  publication-title: Leukemia
– volume: 140
  start-page: 875
  year: 2022
  end-page: 888
  article-title: Aberrant EVI1 splicing contributes to EVI1‐rearranged leukemia
  publication-title: Blood
– volume: 43
  start-page: 1012
  year: 2011
  end-page: 1017
  article-title: Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia
  publication-title: Nat Genet
– volume: 33
  start-page: 800
  year: 2019
  end-page: 804
  article-title: Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1‐positive AML
  publication-title: Leukemia
– volume: 11
  start-page: 352
  year: 1997
  end-page: 358
  article-title: The leukemia‐associated gene MDS1/EVI1 is a new type of GATA‐binding transactivator
  publication-title: Leukemia
– volume: 70
  start-page: 1338
  year: 1987
  end-page: 1342
  article-title: Association of a chromosomal 3; 21 translocation with the blast phase of chronic myelogenous leukemia
  publication-title: Blood
– volume: 68
  start-page: 652
  year: 1986
  end-page: 657
  article-title: Chromosome 3q21 abnormalities associated with hyperactive thrombopoiesis in acute blastic transformation of chronic myeloid leukemia
  publication-title: Blood
– volume: 48
  start-page: 253
  year: 2016
  end-page: 264
  article-title: DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia
  publication-title: Nat Genet
– volume: 22
  start-page: 1519
  year: 2008
  end-page: 1528
  article-title: Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16
  publication-title: Leukemia
– volume: 2
  start-page: 143
  year: 2013
  end-page: 150
  article-title: Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells
  publication-title: Stem Cells Transl Med
– volume: 97
  start-page: 2815
  year: 2001
  end-page: 2822
  article-title: The corepressor CtBP interacts with Evi‐1 to repress transforming growth factor β signaling
  publication-title: Blood
– volume: 308
  start-page: 1171
  year: 2005
  end-page: 1174
  article-title: Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking
  publication-title: Science
– volume: 2
  start-page: 586
  year: 2018
  end-page: 596
  article-title: MECOM‐associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia
  publication-title: Blood Adv
– volume: 122
  start-page: e12
  year: 2013
  end-page: e22
  article-title: Genome‐wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected network of coding and noncoding genes
  publication-title: Blood
– volume: 394
  start-page: 92
  year: 1998
  end-page: 96
  article-title: The oncoprotein Evi‐1 represses TGF‐β signalling by inhibiting Smad3
  publication-title: Nature
– volume: 96
  start-page: 1448
  year: 2011
  end-page: 1456
  article-title: Down‐regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia
  publication-title: Haematologica
– volume: 116
  start-page: 6014
  year: 2010
  end-page: 6017
  article-title: EVI‐1 oncogene expression predicts survival in chronic‐phase CML patients resistant to imatinib treated with second‐generation tyrosine kinase inhibitors
  publication-title: Blood
– volume: 13
  start-page: 348
  year: 1999
  end-page: 357
  article-title: MDS1/EVI1 enhances TGF‐β1 signaling and strengthens its growth‐inhibitory effect, but the leukemia‐associated fusion protein AML1/MDS1/EVI1, product of the t (3; 21), abrogates growth‐inhibition in response to TGF‐β1
  publication-title: Leukemia
– volume: 609
  start-page: 779
  year: 2022
  end-page: 784
  article-title: Independent origins of fetal liver haematopoietic stem and progenitor cells
  publication-title: Nature
– volume: 67
  start-page: 3074
  year: 2007
  end-page: 3084
  article-title: Amplification of MDS1/EVI1 and EVI1, located in the 3q26. 2 amplicon, is associated with favorable patient prognosis in ovarian cancer
  publication-title: Cancer Res
– volume: 117
  start-page: 234
  year: 2011
  end-page: 241
  article-title: Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1
  publication-title: Blood
– volume: 26
  start-page: 7658
  year: 2006
  end-page: 7666
  article-title: Point mutations in two EVI1 Zn fingers abolish EVI1‐GATA1 interaction and allow erythroid differentiation of murine bone marrow cells
  publication-title: Mol Cell Biol
– volume: 91
  start-page: 1221
  year: 2012
  end-page: 1233
  article-title: Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes
  publication-title: Ann Hematol
– volume: 9
  start-page: 1
  year: 2009
  end-page: 12
  article-title: Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
  publication-title: BMC Cancer
– volume: 117
  start-page: e161
  year: 2011
  end-page: e170
  article-title: Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions
  publication-title: Blood
– volume: 57
  start-page: 564
  year: 1997
  end-page: 569
  article-title: Fusion of ETV6 to MDS1/EVI1 as a result of t (3; 12)(q26; p13) in myeloproliferative disorders
  publication-title: Cancer Res
– volume: 36
  start-page: 1573
  year: 2017
  end-page: 1584
  article-title: Ecotropic viral integration site 1, a novel oncogene in prostate cancer
  publication-title: Oncogene
– volume: 153
  start-page: 320
  year: 2013
  end-page: 334
  article-title: Selective inhibition of tumor oncogenes by disruption of super‐enhancers
  publication-title: Cell
– volume: 12
  start-page: 1
  year: 2021
  end-page: 13
  article-title: The leukemic oncogene EVI1 hijacks a MYC super‐enhancer by CTCF‐facilitated loops
  publication-title: Nat Commun
– volume: 27
  start-page: 852
  year: 2013
  end-page: 860
  article-title: Cell of origin determines clinically relevant subtypes of MLL‐rearranged AML
  publication-title: Leukemia
– volume: 276
  start-page: 44936
  year: 2001
  end-page: 44943
  article-title: Interaction of EVI1 with cAMP‐responsive element‐binding protein‐binding protein (CBP) and p300/CBP‐associated factor (P/CAF) results in reversible acetylation of EVI1 and in co‐localization in nuclear speckles
  publication-title: J Biol Chem
– volume: 141
  start-page: 453
  year: 2023
  end-page: 466
  article-title: EVI1 drives leukemogenesis through aberrant ERG activation
  publication-title: Blood
– volume: 153
  start-page: 307
  year: 2013
  end-page: 319
  article-title: Master transcription factors and mediator establish super‐enhancers at key cell identity genes
  publication-title: Cell
– volume: 107
  start-page: 1758
  year: 2020
  end-page: 1772
  article-title: The retinoic acid receptor co‐factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements
  publication-title: Haematologica
– volume: 208
  start-page: 2403
  year: 2011
  end-page: 2416
  article-title: Evi1 is essential for hematopoietic stem cell self‐renewal, and its expression marks hematopoietic cells with long‐term multilineage repopulating activity
  publication-title: J Exp Med
– volume: 10
  start-page: 1961
  year: 1995
  end-page: 1967
  article-title: EVI‐1 zinc finger protein works as a transcriptional activator via binding to a consensus sequence of GACAAGATAAGATAAN1‐28 CTCATCTTC
  publication-title: Oncogene
– volume: 13
  start-page: 1639
  year: 1999
  end-page: 1645
  article-title: Forced expression of the leukemia‐associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements
  publication-title: Leukemia
– volume: 33
  start-page: 5028
  year: 2014
  end-page: 5038
  article-title: Evi1 defines leukemia‐initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia
  publication-title: Oncogene
– volume: 27
  start-page: 1127
  year: 2013
  end-page: 1138
  article-title: Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells
  publication-title: Leukemia
– volume: 69
  start-page: 1633
  year: 2009
  end-page: 1642
  article-title: EVI1 Impairs myelopoiesis by deregulation of PU. 1 function
  publication-title: Cancer Res
– volume: 127
  start-page: 458
  year: 2016
  end-page: 463
  article-title: Primary acute myeloid leukemia cells with overexpression of EVI‐1 are sensitive to all‐trans retinoic acid
  publication-title: Blood
– volume: 7
  start-page: 1577
  year: 2023
  end-page: 1593
  article-title: EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune‐suppressive environment
  publication-title: Blood Adv
– volume: 111
  start-page: 4329
  year: 2008
  end-page: 4337
  article-title: High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated
  publication-title: Blood
– volume: 28
  start-page: 4364
  year: 2009
  end-page: 4374
  article-title: Pbx1 is a downstream target of Evi‐1 in hematopoietic stem/progenitors and leukemic cells
  publication-title: Oncogene
– volume: 97
  start-page: 848
  year: 2015
  end-page: 854
  article-title: Mutations in MECOM, encoding oncoprotein EVI1, cause radioulnar synostosis with amegakaryocytic thrombocytopenia
  publication-title: Am J Hum Genet
– volume: 131
  start-page: 717
  year: 2018
  end-page: 732
  article-title: A landscape of germ line mutations in a cohort of inherited bone marrow failure patients
  publication-title: Blood
– volume: 106
  start-page: 1569
  year: 2021
  end-page: 1580
  article-title: RUNX1‐EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks
  publication-title: Haematologica
– volume: 19
  start-page: 2958
  year: 2000
  end-page: 2968
  article-title: The evi‐1 oncoprotein inhibits c‐Jun N‐terminal kinase and prevents stress‐induced cell death
  publication-title: EMBO J
– volume: 19
  start-page: 1654
  year: 2017
  end-page: 1668
  article-title: RUNX1‐ETO and RUNX1‐EVI1 differentially reprogram the chromatin landscape in t (8; 21) and t (3; 21) AML
  publication-title: Cell Rep
– volume: 162
  start-page: 670
  year: 2013
  end-page: 677
  article-title: High EVI 1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children’s oncology group
  publication-title: Br J Haematol
– volume: 8
  start-page: 301
  year: 1988
  end-page: 308
  article-title: Identification of a common ecotropic viral integration site, Evi‐1, in the DNA of AKXD murine myeloid tumors
  publication-title: Mol Cell Biol
– volume: 24
  start-page: 942
  year: 2010
  end-page: 949
  article-title: EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia
  publication-title: Leukemia
– volume: 9
  start-page: 1
  year: 2018
  end-page: 12
  article-title: EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription
  publication-title: Nat Commun
– volume: 28
  start-page: 2101
  year: 2010
  end-page: 2107
  article-title: High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities
  publication-title: J Clin Oncol
– volume: 6
  start-page: e20793
  year: 2011
  article-title: The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co‐operate in binding and de novo methylation of target DNA
  publication-title: PLoS One
– volume: 76
  start-page: 2594
  year: 1990
  end-page: 2598
  article-title: t (3; 21)(q26; q22): a recurring chromosomal abnormality in therapy‐related myelodysplastic syndrome and acute myeloid leukemia
  publication-title: Blood
– volume: 109
  start-page: 2168
  year: 2012
  end-page: 2173
  article-title: Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors
  publication-title: Proc Natl Acad Sci USA
– volume: 32
  start-page: 2069
  year: 2013
  end-page: 2078
  article-title: Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription
  publication-title: Oncogene
– volume: 30
  start-page: 1290
  year: 2011
  end-page: 1301
  article-title: Control of EVI‐1 oncogene expression in metastatic breast cancer cells through microRNA miR‐22
  publication-title: Oncogene
– volume: 20
  start-page: 1458
  year: 2006
  end-page: 1460
  article-title: Development of megakaryoblastic leukaemia in Runx1‐Evi1 knock‐in chimaeric mouse
  publication-title: Leukemia
– volume: 11
  start-page: 131
  year: 2018
  end-page: 140
  article-title: The bromodomain inhibitor JQ1 enhances the responses to all‐trans retinoic acid in HL‐60 and MV4‐11 leukemia cells
  publication-title: Int J Stem Cells
– volume: 11
  start-page: 1
  year: 2020
  end-page: 14
  article-title: EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self‐renewal
  publication-title: Cell Death Dis
– volume: 18
  start-page: 1108
  year: 2004
  end-page: 1114
  article-title: Translocation t (2; 3)(p15–23; q26–27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features
  publication-title: Leukemia
– volume: 157
  start-page: 369
  year: 2014
  end-page: 381
  article-title: A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
  publication-title: Cell
– volume: 327
  start-page: 1650
  year: 2010
  end-page: 1653
  article-title: The Wnt/β‐catenin pathway is required for the development of leukemia stem cells in AML
  publication-title: Science
– volume: 3
  start-page: 207
  year: 2008
  end-page: 220
  article-title: Evi‐1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells
  publication-title: Cell Stem Cell
– volume: 93
  start-page: 1903
  year: 2008
  end-page: 1907
  article-title: EVI1 overexpression in t (3; 17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22
  publication-title: Haematologica
– volume: 13
  start-page: 4291
  year: 1993
  end-page: 4300
  article-title: Four of the seven zinc fingers of the Evi‐1 myeloid‐transforming gene are required for sequence‐specific binding to GA (C/T) AAGA (T/C) AAGATAA
  publication-title: Mol Cell Biol
– volume: 28
  start-page: 3890
  year: 2010
  end-page: 3898
  article-title: Clinical, molecular, and prognostic significance of WHO type inv (3)(q21q26. 2)/t (3; 3)(q21; q26. 2) and various other 3q abnormalities in acute myeloid leukemia
  publication-title: J Clin Oncol
– volume: 172
  start-page: 870
  year: 2016
  end-page: 878
  article-title: Aberrant EVI 1 expression in acute myeloid leukaemia
  publication-title: Br J Haematol
– volume: 67
  start-page: 5658
  year: 2007
  end-page: 5666
  article-title: Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis
  publication-title: Cancer Res
– volume: 10
  start-page: 788
  year: 1996
  end-page: 794
  article-title: Increased Evi‐1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia
  publication-title: Leukemia
– volume: 31
  start-page: 532
  year: 2017
  end-page: 548.e7
  article-title: Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer
  publication-title: Cancer Cell
– volume: 9
  start-page: 203
  year: 1995
  end-page: 205
  article-title: Expression of the Evi‐1 gene in myelodysplastic syndromes
  publication-title: Leukemia
– volume: 24
  start-page: 69
  year: 2023
  end-page: 83
  article-title: A genetic disorder reveals a hematopoietic stem cell regulatory network co‐opted in leukemia
  publication-title: Nat Immunol
– volume: 16
  start-page: 198
  year: 2010
  end-page: 204
  article-title: Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease
  publication-title: Nat Med
– volume: 101
  start-page: 3872
  year: 2003
  end-page: 3874
  article-title: Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor
  publication-title: Blood
– volume: 280
  start-page: 24227
  year: 2005
  end-page: 24237
  article-title: Repression of bone morphogenetic protein and activin‐inducible transcription by Evi‐1
  publication-title: J Biol Chem
– volume: 33
  start-page: 2454
  year: 2014
  end-page: 2463
  article-title: EVI1 oncogene promotes KRAS pathway through suppression of microRNA‐96 in pancreatic carcinogenesis
  publication-title: Oncogene
– volume: 117
  start-page: 3617
  year: 2011
  end-page: 3628
  article-title: Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins
  publication-title: Blood
– volume: 4
  start-page: e179
  year: 2014
  end-page: e179
  article-title: EVI1 expression in childhood acute lymphoblastic leukaemia is not restricted to MLL and BCR/ABL rearrangements and is influenced by age
  publication-title: Blood Cancer J
– volume: 140
  start-page: 1200
  year: 2022
  end-page: 1228
  article-title: International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
  publication-title: Blood
– volume: 25
  start-page: 415
  year: 2014
  end-page: 427
  article-title: A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv (3)(q21; q26) by activating EVI1 expression
  publication-title: Cancer Cell
– volume: 51
  start-page: 1079
  year: 2012
  end-page: 1085
  article-title: Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases
  publication-title: Genes Chromosomes Cancer
– volume: 20
  start-page: 48
  year: 2006
  end-page: 54
  article-title: Characterization of a recurrent translocation t (2; 3)(p15–22; q26) occurring in acute myeloid leukaemia
  publication-title: Leukemia
– volume: 130
  start-page: 908
  year: 2017
  end-page: 919
  article-title: GATA2 haploinsufficiency accelerates EVI1‐driven leukemogenesis
  publication-title: Blood
– volume: 269
  start-page: 24020
  year: 1994
  end-page: 24026
  article-title: Evi‐1 raises AP‐1 activity and stimulates c‐fos promoter transactivation with dependence on the second zinc finger domain
  publication-title: J Biol Chem
– volume: 9
  start-page: e89397
  year: 2014
  article-title: Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects
  publication-title: PLoS One
– volume: 54
  start-page: 831
  year: 1988
  end-page: 840
  article-title: Retroviral activation of a novel gene encoding a zinc finger protein in IL‐3‐dependent myeloid leukemia cell lines
  publication-title: Cell
– volume: 31
  start-page: 95
  year: 2013
  end-page: 103
  article-title: Deregulated expression of EVI1 defines a poor prognostic subset of MLL‐rearranged acute myeloid leukemias: a study of the German‐Austrian Acute Myeloid Leukemia Study Group and the Dutch‐Belgian‐Swiss HOVON/SAKK Cooperative Group
  publication-title: J Clin Oncol
– volume: 47
  start-page: 288
  year: 2008
  end-page: 298
  article-title: Expression and prognostic significance of different mRNA 5′‐end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration
  publication-title: Genes Chromosomes Cancer
– volume: 40
  start-page: 141
  year: 2008
  end-page: 147
  article-title: Significant increase of self‐renewal in hematopoietic cells after forced expression of EVI1
  publication-title: Blood Cells Mol Dis
– volume: 4
  start-page: e471
  year: 2020
  article-title: High EVI1 expression due to NRIP1/EVI1 fusion in therapy‐related acute myeloid leukemia: description of the first pediatric case
  publication-title: HemaSphere
– volume: 83
  start-page: 78
  year: 2004
  end-page: 83
  article-title: A novel chromosomal translocation t (3; 7)(q26; q21) in myeloid leukemia resulting in overexpression of EVI1
  publication-title: Ann Hematol
– volume: 5
  start-page: 221
  year: 1990
  end-page: 231
  article-title: The human Evi‐1 gene is located on chromosome 3q24‐q28 but is not rearranged in three cases of acute nonlymphocytic leukemias containing t (3; 5)(q25; q34) translocations
  publication-title: Oncogene Res
– volume: 106
  start-page: 1569
  year: 2021
  end-page: 1580
  ident: R73
  article-title: RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks.
  publication-title: Haematologica
– volume: 47
  start-page: 288
  year: 2008
  end-page: 298
  ident: R24
  article-title: Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
  publication-title: Genes Chromosomes Cancer
– volume: 16
  start-page: 198
  year: 2010
  end-page: 204
  ident: R104
  article-title: Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.
  publication-title: Nat Med
– volume: 109
  start-page: 2168
  year: 2012
  end-page: 2173
  ident: R53
  article-title: Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.
  publication-title: Proc Natl Acad Sci USA
– volume: 204
  start-page: 392
  year: 2011
  end-page: 397
  ident: R39
  article-title: Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.
  publication-title: Cancer Genet
– volume: 20
  start-page: 1458
  year: 2006
  end-page: 1460
  ident: R71
  article-title: Development of megakaryoblastic leukaemia in Runx1-Evi1 knock-in chimaeric mouse.
  publication-title: Leukemia
– volume: 10
  start-page: eaao3003
  year: 2018
  ident: R118
  article-title: Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
  publication-title: Sci Transl Med
– volume: 7
  start-page: 121
  year: 2019
  end-page: 130
  ident: R115
  article-title: Efficacy of All-Trans-Retinoic Acid in high-risk acute myeloid leukemia with overexpression of EVI1.
  publication-title: Oncol Ther
– volume: 172
  start-page: 870
  year: 2016
  end-page: 878
  ident: R8
  article-title: Aberrant EVI 1 expression in acute myeloid leukaemia.
  publication-title: Br J Haematol
– volume: 133
  start-page: 92
  year: 2010
  end-page: 100
  ident: R96
  article-title: Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with Fanconi anemia: morphologic and cytogenetic characteristics.
  publication-title: Am J Clin Pathol
– volume: 117
  start-page: 6047
  year: 2011
  end-page: 6050
  ident: R94
  article-title: Fanconi anemia (FA)-associated 3q gains in leukemic transformation consistently target EVI1, but do not affect low TERC expression in FA.
  publication-title: Blood
– volume: 162
  start-page: 670
  year: 2013
  end-page: 677
  ident: R29
  article-title: High EVI 1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.
  publication-title: Br J Haematol
– volume: 269
  start-page: 24020
  year: 1994
  end-page: 24026
  ident: R64
  article-title: Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain.
  publication-title: J Biol Chem
– volume: 101
  start-page: 3872
  year: 2003
  end-page: 3874
  ident: R97
  article-title: Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor.
  publication-title: Blood
– volume: 136
  start-page: 224
  year: 2020
  end-page: 234
  ident: R85
  article-title: Atypical 3q26/MECOM rearrangements genocopy inv (3)/t (3; 3) in acute myeloid leukemia.
  publication-title: Blood
– volume: 208
  start-page: 2403
  year: 2011
  end-page: 2416
  ident: R14
  article-title: Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity.
  publication-title: J Exp Med
– volume: 280
  start-page: 24227
  year: 2005
  end-page: 24237
  ident: R57
  article-title: Repression of bone morphogenetic protein and activin-inducible transcription by Evi-1.
  publication-title: J Biol Chem
– volume: 51
  start-page: 1079
  year: 2012
  end-page: 1085
  ident: R88
  article-title: Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
  publication-title: Genes Chromosomes Cancer
– volume: 97
  start-page: 2815
  year: 2001
  end-page: 2822
  ident: R55
  article-title: The corepressor CtBP interacts with Evi-1 to repress transforming growth factor β signaling.
  publication-title: Blood
– volume: 96
  start-page: 1448
  year: 2011
  end-page: 1456
  ident: R27
  article-title: Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
  publication-title: Haematologica
– volume: 10
  start-page: 1500
  year: 2020
  end-page: 1513
  ident: R68
  article-title: Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition.
  publication-title: Cancer Discov
– volume: 70
  start-page: 1338
  year: 1987
  end-page: 1342
  ident: R69
  article-title: Association of a chromosomal 3; 21 translocation with the blast phase of chronic myelogenous leukemia.
  publication-title: Blood
– volume: 127
  start-page: 458
  year: 2016
  end-page: 463
  ident: R113
  article-title: Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid.
  publication-title: Blood
– volume: 11
  start-page: 352
  year: 1997
  end-page: 358
  ident: R4
  article-title: The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
  publication-title: Leukemia
– volume: 23
  start-page: 301
  year: 2017
  end-page: 313
  ident: R116
  article-title: The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
  publication-title: Nat Med
– volume: 117
  start-page: e161
  year: 2011
  end-page: e170
  ident: R95
  article-title: Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.
  publication-title: Blood
– volume: 9
  start-page: e89397
  year: 2014
  ident: R12
  article-title: Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects.
  publication-title: PLoS One
– volume: 27
  start-page: 1127
  year: 2013
  end-page: 1138
  ident: R23
  article-title: Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells.
  publication-title: Leukemia
– volume: 604
  start-page: 534
  year: 2022
  end-page: 540
  ident: R16
  article-title: Mapping human haematopoietic stem cells from haemogenic endothelium to birth.
  publication-title: Nature
– volume: 28
  start-page: 4364
  year: 2009
  end-page: 4374
  ident: R52
  article-title: Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells.
  publication-title: Oncogene
– volume: 31
  start-page: 532
  year: 2017
  end-page: 548.e7
  ident: R117
  article-title: Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer.
  publication-title: Cancer Cell
– volume: 140
  start-page: 875
  year: 2022
  end-page: 888
  ident: R82
  article-title: Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
  publication-title: Blood
– volume: 153
  start-page: 307
  year: 2013
  end-page: 319
  ident: R111
  article-title: Master transcription factors and mediator establish super-enhancers at key cell identity genes.
  publication-title: Cell
– volume: 13
  start-page: 4291
  year: 1993
  end-page: 4300
  ident: R1
  article-title: Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA (C/T) AAGA (T/C) AAGATAA.
  publication-title: Mol Cell Biol
– volume: 276
  start-page: 44936
  year: 2001
  end-page: 44943
  ident: R58
  article-title: Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles.
  publication-title: J Biol Chem
– volume: 19
  start-page: 1654
  year: 2017
  end-page: 1668
  ident: R72
  article-title: RUNX1-ETO and RUNX1-EVI1 differentially reprogram the chromatin landscape in t (8; 21) and t (3; 21) AML.
  publication-title: Cell Rep
– volume: 28
  start-page: 3890
  year: 2010
  end-page: 3898
  ident: R32
  article-title: Clinical, molecular, and prognostic significance of WHO type inv (3)(q21q26. 2)/t (3; 3)(q21; q26. 2) and various other 3q abnormalities in acute myeloid leukemia.
  publication-title: J Clin Oncol
– volume: 24
  start-page: 81
  year: 2010
  end-page: 88
  ident: R59
  article-title: EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization.
  publication-title: Leukemia
– volume: 140
  start-page: 1200
  year: 2022
  end-page: 1228
  ident: R75
  article-title: International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
  publication-title: Blood
– volume: 47
  start-page: 1225
  year: 2019
  end-page: 1238
  ident: R7
  article-title: Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex.
  publication-title: Nucleic Acids Res
– volume: 54
  start-page: 831
  year: 1988
  end-page: 840
  ident: R101
  article-title: Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines.
  publication-title: Cell
– volume: 40
  start-page: 141
  year: 2008
  end-page: 147
  ident: R17
  article-title: Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1.
  publication-title: Blood Cells Mol Dis
– volume: 97
  start-page: 848
  year: 2015
  end-page: 854
  ident: R21
  article-title: Mutations in MECOM, encoding oncoprotein EVI1, cause radioulnar synostosis with amegakaryocytic thrombocytopenia.
  publication-title: Am J Hum Genet
– volume: 10
  start-page: 788
  year: 1996
  end-page: 794
  ident: R37
  article-title: Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia.
  publication-title: Leukemia
– volume: 25
  start-page: 415
  year: 2014
  end-page: 427
  ident: R78
  article-title: A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv (3)(q21; q26) by activating EVI1 expression.
  publication-title: Cancer Cell
– volume: 20
  start-page: 48
  year: 2006
  end-page: 54
  ident: R93
  article-title: Characterization of a recurrent translocation t (2; 3)(p15-22; q26) occurring in acute myeloid leukaemia.
  publication-title: Leukemia
– volume: 111
  start-page: 4329
  year: 2008
  end-page: 4337
  ident: R25
  article-title: High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
  publication-title: Blood
– volume: 68
  start-page: 652
  year: 1986
  end-page: 657
  ident: R76
  article-title: Chromosome 3q21 abnormalities associated with hyperactive thrombopoiesis in acute blastic transformation of chronic myeloid leukemia.
  publication-title: Blood
– volume: 141
  start-page: 453
  year: 2023
  end-page: 466
  ident: R50
  article-title: EVI1 drives leukemogenesis through aberrant ERG activation.
  publication-title: Blood
– volume: 122
  start-page: e12
  year: 2013
  end-page: e22
  ident: R84
  article-title: Genome-wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected network of coding and noncoding genes.
  publication-title: Blood
– volume: 394
  start-page: 92
  year: 1998
  end-page: 96
  ident: R56
  article-title: The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3.
  publication-title: Nature
– volume: 327
  start-page: 1650
  year: 2010
  end-page: 1653
  ident: R105
  article-title: The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML.
  publication-title: Science
– volume: 18
  start-page: 1108
  year: 2004
  end-page: 1114
  ident: R92
  article-title: Translocation t (2; 3)(p15-23; q26-27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features.
  publication-title: Leukemia
– volume: 131
  start-page: 717
  year: 2018
  end-page: 732
  ident: R22
  article-title: A landscape of germ line mutations in a cohort of inherited bone marrow failure patients.
  publication-title: Blood
– volume: 28
  start-page: 2101
  year: 2010
  end-page: 2107
  ident: R26
  article-title: High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
  publication-title: J Clin Oncol
– volume: 9
  start-page: 1
  year: 2009
  end-page: 12
  ident: R44
  article-title: Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.
  publication-title: BMC Cancer
– volume: 52
  start-page: 255
  year: 2013
  end-page: 264
  ident: R47
  article-title: Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.
  publication-title: Mol Carcinog
– volume: 65
  start-page: 55
  year: 1997
  end-page: 70
  ident: R11
  article-title: The Evil proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development.
  publication-title: Mech Dev
– volume: 6
  start-page: e20793
  year: 2011
  ident: R60
  article-title: The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA.
  publication-title: PLoS One
– volume: 33
  start-page: 2454
  year: 2014
  end-page: 2463
  ident: R46
  article-title: EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
  publication-title: Oncogene
– volume: 11
  start-page: 1
  year: 2020
  end-page: 14
  ident: R10
  article-title: EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal.
  publication-title: Cell Death Dis
– volume: 153
  start-page: 320
  year: 2013
  end-page: 334
  ident: R110
  article-title: Selective inhibition of tumor oncogenes by disruption of super-enhancers.
  publication-title: Cell
– volume: 130
  start-page: 908
  year: 2017
  end-page: 919
  ident: R79
  article-title: GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
  publication-title: Blood
– volume: 42
  start-page: D172
  year: 2014
  end-page: D177
  ident: R87
  article-title: BloodChIP: a database of comparative genome-wide transcription factor binding profiles in human blood cells.
  publication-title: Nucleic Acids Res
– volume: 101
  start-page: 837
  year: 2003
  end-page: 845
  ident: R31
  article-title: High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
  publication-title: Blood
– volume: 12
  start-page: 1
  year: 2020
  end-page: 19
  ident: R108
  article-title: Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL.
  publication-title: Genome Med
– volume: 107
  start-page: 1758
  year: 2020
  end-page: 1772
  ident: R90
  article-title: The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements.
  publication-title: Haematologica
– volume: 69
  start-page: 1633
  year: 2009
  end-page: 1642
  ident: R62
  article-title: EVI1 Impairs myelopoiesis by deregulation of PU. 1 function.
  publication-title: Cancer Res
– volume: 67
  start-page: 5658
  year: 2007
  end-page: 5666
  ident: R65
  article-title: Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
  publication-title: Cancer Res
– volume: 13
  start-page: 348
  year: 1999
  end-page: 357
  ident: R6
  article-title: MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t (3; 21), abrogates growth-inhibition in response to TGF-β1.
  publication-title: Leukemia
– volume: 117
  start-page: 3617
  year: 2011
  end-page: 3628
  ident: R54
  article-title: Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
  publication-title: Blood
– volume: 32
  start-page: 2069
  year: 2013
  end-page: 2078
  ident: R98
  article-title: Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
  publication-title: Oncogene
– volume: 9
  start-page: 203
  year: 1995
  end-page: 205
  ident: R35
  article-title: Expression of the Evi-1 gene in myelodysplastic syndromes.
  publication-title: Leukemia
– volume: 110
  start-page: E2885
  year: 2013
  end-page: E2894
  ident: R9
  article-title: EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation.
  publication-title: Proc Natl Acad Sci USA
– volume: 33
  start-page: 5028
  year: 2014
  end-page: 5038
  ident: R40
  article-title: Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
  publication-title: Oncogene
– volume: 10
  start-page: 1961
  year: 1995
  end-page: 1967
  ident: R3
  article-title: EVI-1 zinc finger protein works as a transcriptional activator via binding to a consensus sequence of GACAAGATAAGATAAN1-28 CTCATCTTC.
  publication-title: Oncogene
– volume: 24
  start-page: 942
  year: 2010
  end-page: 949
  ident: R33
  article-title: EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
  publication-title: Leukemia
– volume: 4
  start-page: e471
  year: 2020
  ident: R89
  article-title: High EVI1 expression due to NRIP1/EVI1 fusion in therapy-related acute myeloid leukemia: description of the first pediatric case.
  publication-title: HemaSphere
– volume: 4
  start-page: e179
  year: 2014
  end-page: e179
  ident: R42
  article-title: EVI1 expression in childhood acute lymphoblastic leukaemia is not restricted to MLL and BCR/ABL rearrangements and is influenced by age.
  publication-title: Blood Cancer J
– volume: 35
  start-page: 3127
  year: 2021
  end-page: 3138
  ident: R112
  article-title: Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
  publication-title: Leukemia
– volume: 24
  start-page: 1976
  year: 2005
  end-page: 1987
  ident: R13
  article-title: Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.
  publication-title: EMBO J
– volume: 8
  start-page: 301
  year: 1988
  end-page: 308
  ident: R100
  article-title: Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors.
  publication-title: Mol Cell Biol
– volume: 19
  start-page: 2958
  year: 2000
  end-page: 2968
  ident: R67
  article-title: The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.
  publication-title: EMBO J
– volume: 157
  start-page: 369
  year: 2014
  end-page: 381
  ident: R77
  article-title: A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
  publication-title: Cell
– volume: 27
  start-page: 852
  year: 2013
  end-page: 860
  ident: R106
  article-title: Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
  publication-title: Leukemia
– volume: 24
  start-page: 69
  year: 2023
  end-page: 83
  ident: R19
  article-title: A genetic disorder reveals a hematopoietic stem cell regulatory network co-opted in leukemia.
  publication-title: Nat Immunol
– volume: 308
  start-page: 1171
  year: 2005
  end-page: 1174
  ident: R103
  article-title: Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.
  publication-title: Science
– volume: 2
  start-page: 143
  year: 2013
  end-page: 150
  ident: R107
  article-title: Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.
  publication-title: Stem Cells Transl Med
– volume: 5
  start-page: 221
  year: 1990
  end-page: 231
  ident: R2
  article-title: The human Evi-1 gene is located on chromosome 3q24-q28 but is not rearranged in three cases of acute nonlymphocytic leukemias containing t (3; 5)(q25; q34) translocations.
  publication-title: Oncogene Res
– volume: 33
  start-page: 800
  year: 2019
  end-page: 804
  ident: R66
  article-title: Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.
  publication-title: Leukemia
– volume: 93
  start-page: 1903
  year: 2008
  end-page: 1907
  ident: R91
  article-title: EVI1 overexpression in t (3; 17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.
  publication-title: Haematologica
– volume: 13
  start-page: 1639
  year: 1999
  end-page: 1645
  ident: R5
  article-title: Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
  publication-title: Leukemia
– volume: 11
  start-page: 131
  year: 2018
  end-page: 140
  ident: R114
  article-title: The bromodomain inhibitor JQ1 enhances the responses to all-trans retinoic acid in HL-60 and MV4-11 leukemia cells.
  publication-title: Int J Stem Cells
– volume: 22
  start-page: 1519
  year: 2008
  end-page: 1528
  ident: R102
  article-title: Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.
  publication-title: Leukemia
– volume: 116
  start-page: 6014
  year: 2010
  end-page: 6017
  ident: R38
  article-title: EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
  publication-title: Blood
– volume: 31
  start-page: 95
  year: 2013
  end-page: 103
  ident: R30
  article-title: Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
  publication-title: J Clin Oncol
– volume: 91
  start-page: 1221
  year: 2012
  end-page: 1233
  ident: R36
  article-title: Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
  publication-title: Ann Hematol
– volume: 57
  start-page: 564
  year: 1997
  end-page: 569
  ident: R74
  article-title: Fusion of ETV6 to MDS1/EVI1 as a result of t (3; 12)(q26; p13) in myeloproliferative disorders.
  publication-title: Cancer Res
– volume: 48
  start-page: 253
  year: 2016
  end-page: 264
  ident: R109
  article-title: DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia.
  publication-title: Nat Genet
– volume: 3
  start-page: 207
  year: 2008
  end-page: 220
  ident: R18
  article-title: Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells.
  publication-title: Cell Stem Cell
– volume: 609
  start-page: 779
  year: 2022
  end-page: 784
  ident: R15
  article-title: Independent origins of fetal liver haematopoietic stem and progenitor cells.
  publication-title: Nature
– volume: 2
  start-page: 586
  year: 2018
  end-page: 596
  ident: R20
  article-title: MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia.
  publication-title: Blood Adv
– volume: 117
  start-page: 234
  year: 2011
  end-page: 241
  ident: R61
  article-title: Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
  publication-title: Blood
– volume: 117
  start-page: 6304
  year: 2011
  end-page: 6314
  ident: R99
  article-title: Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
  publication-title: Blood
– volume: 76
  start-page: 2594
  year: 1990
  end-page: 2598
  ident: R70
  article-title: t (3; 21)(q26; q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia.
  publication-title: Blood
– volume: 67
  start-page: 3074
  year: 2007
  end-page: 3084
  ident: R43
  article-title: Amplification of MDS1/EVI1 and EVI1, located in the 3q26. 2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
  publication-title: Cancer Res
– volume: 36
  start-page: 2927
  year: 2022
  end-page: 2930
  ident: R81
  article-title: SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase.
  publication-title: Leukemia
– volume: 83
  start-page: 78
  year: 2004
  end-page: 83
  ident: R86
  article-title: A novel chromosomal translocation t (3; 7)(q26; q21) in myeloid leukemia resulting in overexpression of EVI1.
  publication-title: Ann Hematol
– volume: 27
  start-page: 56
  year: 2013
  end-page: 65
  ident: R41
  article-title: EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.
  publication-title: Leukemia
– volume: 12
  start-page: 1
  year: 2021
  end-page: 13
  ident: R83
  article-title: The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
  publication-title: Nat Commun
– volume: 9
  start-page: 1
  year: 2018
  end-page: 12
  ident: R49
  article-title: EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription.
  publication-title: Nat Commun
– volume: 7
  start-page: 1577
  year: 2023
  end-page: 1593
  ident: R51
  article-title: EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
  publication-title: Blood Adv
– volume: 127
  start-page: 2391
  year: 2016
  end-page: 2405
  ident: R28
  article-title: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
  publication-title: Blood
– volume: 43
  start-page: 1012
  year: 2011
  end-page: 1017
  ident: R80
  article-title: Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.
  publication-title: Nat Genet
– volume: 84
  start-page: 1243
  year: 1994
  end-page: 1248
  ident: R34
  article-title: Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
  publication-title: Blood
– volume: 36
  start-page: 1573
  year: 2017
  end-page: 1584
  ident: R48
  article-title: Ecotropic viral integration site 1, a novel oncogene in prostate cancer.
  publication-title: Oncogene
– volume: 30
  start-page: 1290
  year: 2011
  end-page: 1301
  ident: R45
  article-title: Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.
  publication-title: Oncogene
– volume: 26
  start-page: 7658
  year: 2006
  end-page: 7666
  ident: R63
  article-title: Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells.
  publication-title: Mol Cell Biol
– volume: 25
  start-page: 415
  year: 2014
  ident: R78-20231004
  article-title: A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv (3)(q21; q26) by activating EVI1 expression.
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2014.02.008
– volume: 83
  start-page: 78
  year: 2004
  ident: R86-20231004
  article-title: A novel chromosomal translocation t (3; 7)(q26; q21) in myeloid leukemia resulting in overexpression of EVI1.
  publication-title: Ann Hematol
  doi: 10.1007/s00277-003-0778-y
– volume: 13
  start-page: 4291
  year: 1993
  ident: R1-20231004
  article-title: Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA (C/T) AAGA (T/C) AAGATAA.
  publication-title: Mol Cell Biol
– volume: 394
  start-page: 92
  year: 1998
  ident: R56-20231004
  article-title: The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3.
  publication-title: Nature
  doi: 10.1038/27945
– volume: 4
  start-page: e471
  year: 2020
  ident: R89-20231004
  article-title: High EVI1 expression due to NRIP1/EVI1 fusion in therapy-related acute myeloid leukemia: description of the first pediatric case.
  publication-title: HemaSphere
  doi: 10.1097/HS9.0000000000000471
– volume: 280
  start-page: 24227
  year: 2005
  ident: R57-20231004
  article-title: Repression of bone morphogenetic protein and activin-inducible transcription by Evi-1.
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M414305200
– volume: 31
  start-page: 95
  year: 2013
  ident: R30-20231004
  article-title: Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.41.5505
– volume: 8
  start-page: 301
  year: 1988
  ident: R100-20231004
  article-title: Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors.
  publication-title: Mol Cell Biol
– volume: 18
  start-page: 1108
  year: 2004
  ident: R92-20231004
  article-title: Translocation t (2; 3)(p15–23; q26–27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features.
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2403346
– volume: 19
  start-page: 2958
  year: 2000
  ident: R67-20231004
  article-title: The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.
  publication-title: EMBO J
  doi: 10.1093/emboj/19.12.2958
– volume: 9
  start-page: e89397
  year: 2014
  ident: R12-20231004
  article-title: Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects.
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0089397
– volume: 32
  start-page: 2069
  year: 2013
  ident: R98-20231004
  article-title: Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
  publication-title: Oncogene
  doi: 10.1038/onc.2012.222
– volume: 52
  start-page: 255
  year: 2013
  ident: R47-20231004
  article-title: Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.
  publication-title: Mol Carcinog
  doi: 10.1002/mc.21852
– volume: 10
  start-page: eaao3003
  year: 2018
  ident: R118-20231004
  article-title: Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aao3003
– volume: 117
  start-page: 6047
  year: 2011
  ident: R94-20231004
  article-title: Fanconi anemia (FA)–associated 3q gains in leukemic transformation consistently target EVI1, but do not affect low TERC expression in FA.
  publication-title: Blood
  doi: 10.1182/blood-2011-03-343897
– volume: 4
  start-page: e179
  year: 2014
  ident: R42-20231004
  article-title: EVI1 expression in childhood acute lymphoblastic leukaemia is not restricted to MLL and BCR/ABL rearrangements and is influenced by age.
  publication-title: Blood Cancer J
  doi: 10.1038/bcj.2013.76
– volume: 42
  start-page: D172
  issue: D1
  year: 2014
  ident: R87-20231004
  article-title: BloodChIP: a database of comparative genome-wide transcription factor binding profiles in human blood cells.
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkt1036
– volume: 204
  start-page: 392
  year: 2011
  ident: R39-20231004
  article-title: Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.
  publication-title: Cancer Genet
  doi: 10.1016/j.cancergen.2011.06.002
– volume: 33
  start-page: 800
  year: 2019
  ident: R66-20231004
  article-title: Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.
  publication-title: Leukemia
  doi: 10.1038/s41375-018-0291-x
– volume: 13
  start-page: 348
  year: 1999
  ident: R6-20231004
  article-title: MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t (3; 21), abrogates growth-inhibition in response to TGF-β1.
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2401360
– volume: 107
  start-page: 1758
  year: 2020
  ident: R90-20231004
  article-title: The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements.
  publication-title: Haematologica
  doi: 10.3324/haematol.2021.276048
– volume: 609
  start-page: 779
  year: 2022
  ident: R15-20231004
  article-title: Independent origins of fetal liver haematopoietic stem and progenitor cells.
  publication-title: Nature
  doi: 10.1038/s41586-022-05203-0
– volume: 33
  start-page: 2454
  year: 2014
  ident: R46-20231004
  article-title: EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
  publication-title: Oncogene
  doi: 10.1038/onc.2013.204
– volume: 140
  start-page: 875
  year: 2022
  ident: R82-20231004
  article-title: Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
  publication-title: Blood
  doi: 10.1182/blood.2021015325
– volume: 116
  start-page: 6014
  year: 2010
  ident: R38-20231004
  article-title: EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
  publication-title: Blood
  doi: 10.1182/blood-2010-01-264234
– volume: 26
  start-page: 7658
  year: 2006
  ident: R63-20231004
  article-title: Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells.
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.00363-06
– volume: 12
  start-page: 1
  year: 2021
  ident: R83-20231004
  article-title: The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-25862-3
– volume: 69
  start-page: 1633
  year: 2009
  ident: R62-20231004
  article-title: EVI1 Impairs myelopoiesis by deregulation of PU. 1 function.
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-2562
– volume: 20
  start-page: 1458
  year: 2006
  ident: R71-20231004
  article-title: Development of megakaryoblastic leukaemia in Runx1-Evi1 knock-in chimaeric mouse.
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404281
– volume: 70
  start-page: 1338
  year: 1987
  ident: R69-20231004
  article-title: Association of a chromosomal 3; 21 translocation with the blast phase of chronic myelogenous leukemia.
  publication-title: Blood
  doi: 10.1182/blood.V70.5.1338.1338
– volume: 157
  start-page: 369
  year: 2014
  ident: R77-20231004
  article-title: A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
  publication-title: Cell
  doi: 10.1016/j.cell.2014.02.019
– volume: 141
  start-page: 453
  year: 2023
  ident: R50-20231004
  article-title: EVI1 drives leukemogenesis through aberrant ERG activation.
  publication-title: Blood
  doi: 10.1182/blood.2022016592
– volume: 28
  start-page: 4364
  year: 2009
  ident: R52-20231004
  article-title: Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells.
  publication-title: Oncogene
  doi: 10.1038/onc.2009.288
– volume: 48
  start-page: 253
  year: 2016
  ident: R109-20231004
  article-title: DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia.
  publication-title: Nat Genet
  doi: 10.1038/ng.3488
– volume: 269
  start-page: 24020
  year: 1994
  ident: R64-20231004
  article-title: Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain.
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(19)51041-9
– volume: 276
  start-page: 44936
  year: 2001
  ident: R58-20231004
  article-title: Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles.
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M106733200
– volume: 11
  start-page: 131
  year: 2018
  ident: R114-20231004
  article-title: The bromodomain inhibitor JQ1 enhances the responses to all-trans retinoic acid in HL-60 and MV4-11 leukemia cells.
  publication-title: Int J Stem Cells
  doi: 10.15283/ijsc18021
– volume: 109
  start-page: 2168
  year: 2012
  ident: R53-20231004
  article-title: Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1119229109
– volume: 5
  start-page: 221
  year: 1990
  ident: R2-20231004
  article-title: The human Evi-1 gene is located on chromosome 3q24-q28 but is not rearranged in three cases of acute nonlymphocytic leukemias containing t (3; 5)(q25; q34) translocations.
  publication-title: Oncogene Res
– volume: 172
  start-page: 870
  year: 2016
  ident: R8-20231004
  article-title: Aberrant EVI 1 expression in acute myeloid leukaemia.
  publication-title: Br J Haematol
  doi: 10.1111/bjh.13898
– volume: 51
  start-page: 1079
  year: 2012
  ident: R88-20231004
  article-title: Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
  publication-title: Genes Chromosomes Cancer
  doi: 10.1002/gcc.21992
– volume: 16
  start-page: 198
  year: 2010
  ident: R104-20231004
  article-title: Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.
  publication-title: Nat Med
  doi: 10.1038/nm.2088
– volume: 110
  start-page: E2885
  year: 2013
  ident: R9-20231004
  article-title: EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation.
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1309310110
– volume: 47
  start-page: 288
  year: 2008
  ident: R24-20231004
  article-title: Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
  publication-title: Genes Chromosomes Cancer
  doi: 10.1002/gcc.20532
– volume: 31
  start-page: 532
  year: 2017
  ident: R117-20231004
  article-title: Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer.
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.02.017
– volume: 97
  start-page: 2815
  year: 2001
  ident: R55-20231004
  article-title: The corepressor CtBP interacts with Evi-1 to repress transforming growth factor β signaling.
  publication-title: Blood
  doi: 10.1182/blood.V97.9.2815
– volume: 308
  start-page: 1171
  year: 2005
  ident: R103-20231004
  article-title: Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.
  publication-title: Science
  doi: 10.1126/science.1105063
– volume: 111
  start-page: 4329
  year: 2008
  ident: R25-20231004
  article-title: High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
  publication-title: Blood
  doi: 10.1182/blood-2007-10-119230
– volume: 106
  start-page: 1569
  year: 2021
  ident: R73-20231004
  article-title: RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks.
  publication-title: Haematologica
  doi: 10.3324/haematol.2019.241885
– volume: 9
  start-page: 1
  year: 2018
  ident: R49-20231004
  article-title: EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription.
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-06208-y
– volume: 9
  start-page: 203
  year: 1995
  ident: R35-20231004
  article-title: Expression of the Evi-1 gene in myelodysplastic syndromes.
  publication-title: Leukemia
– volume: 117
  start-page: 234
  year: 2011
  ident: R61-20231004
  article-title: Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
  publication-title: Blood
  doi: 10.1182/blood-2010-04-281337
– volume: 93
  start-page: 1903
  year: 2008
  ident: R91-20231004
  article-title: EVI1 overexpression in t (3; 17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.
  publication-title: Haematologica
  doi: 10.3324/haematol.13192
– volume: 30
  start-page: 1290
  year: 2011
  ident: R45-20231004
  article-title: Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.
  publication-title: Oncogene
  doi: 10.1038/onc.2010.510
– volume: 12
  start-page: 1
  year: 2020
  ident: R108-20231004
  article-title: Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL.
  publication-title: Genome Med
  doi: 10.1186/s13073-020-00724-7
– volume: 68
  start-page: 652
  year: 1986
  ident: R76-20231004
  article-title: Chromosome 3q21 abnormalities associated with hyperactive thrombopoiesis in acute blastic transformation of chronic myeloid leukemia.
  publication-title: Blood
  doi: 10.1182/blood.V68.3.652.652
– volume: 153
  start-page: 320
  year: 2013
  ident: R110-20231004
  article-title: Selective inhibition of tumor oncogenes by disruption of super-enhancers.
  publication-title: Cell
  doi: 10.1016/j.cell.2013.03.036
– volume: 101
  start-page: 3872
  year: 2003
  ident: R97-20231004
  article-title: Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor.
  publication-title: Blood
  doi: 10.1182/blood-2002-10-3243
– volume: 127
  start-page: 458
  year: 2016
  ident: R113-20231004
  article-title: Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid.
  publication-title: Blood
  doi: 10.1182/blood-2015-07-653840
– volume: 22
  start-page: 1519
  year: 2008
  ident: R102-20231004
  article-title: Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.
  publication-title: Leukemia
  doi: 10.1038/leu.2008.118
– volume: 27
  start-page: 56
  year: 2013
  ident: R41-20231004
  article-title: EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.
  publication-title: Leukemia
  doi: 10.1038/leu.2012.211
– volume: 35
  start-page: 3127
  year: 2021
  ident: R112-20231004
  article-title: Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
  publication-title: Leukemia
  doi: 10.1038/s41375-021-01235-z
– volume: 13
  start-page: 1639
  year: 1999
  ident: R5-20231004
  article-title: Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2401585
– volume: 47
  start-page: 1225
  year: 2019
  ident: R7-20231004
  article-title: Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex.
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gky1192
– volume: 7
  start-page: 121
  year: 2019
  ident: R115-20231004
  article-title: Efficacy of All-Trans-Retinoic Acid in high-risk acute myeloid leukemia with overexpression of EVI1.
  publication-title: Oncol Ther
  doi: 10.1007/s40487-019-0095-9
– volume: 36
  start-page: 1573
  year: 2017
  ident: R48-20231004
  article-title: Ecotropic viral integration site 1, a novel oncogene in prostate cancer.
  publication-title: Oncogene
  doi: 10.1038/onc.2016.325
– volume: 28
  start-page: 2101
  year: 2010
  ident: R26-20231004
  article-title: High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.26.0646
– volume: 33
  start-page: 5028
  year: 2014
  ident: R40-20231004
  article-title: Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
  publication-title: Oncogene
  doi: 10.1038/onc.2014.108
– volume: 84
  start-page: 1243
  year: 1994
  ident: R34-20231004
  article-title: Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
  publication-title: Blood
  doi: 10.1182/blood.V84.4.1243.1243
– volume: 67
  start-page: 5658
  year: 2007
  ident: R65-20231004
  article-title: Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-3962
– volume: 40
  start-page: 141
  year: 2008
  ident: R17-20231004
  article-title: Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1.
  publication-title: Blood Cells Mol Dis
  doi: 10.1016/j.bcmd.2007.07.012
– volume: 10
  start-page: 1500
  year: 2020
  ident: R68-20231004
  article-title: Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition.
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-19-1469
– volume: 117
  start-page: 6304
  year: 2011
  ident: R99-20231004
  article-title: Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
  publication-title: Blood
  doi: 10.1182/blood-2009-07-234310
– volume: 604
  start-page: 534
  year: 2022
  ident: R16-20231004
  article-title: Mapping human haematopoietic stem cells from haemogenic endothelium to birth.
  publication-title: Nature
  doi: 10.1038/s41586-022-04571-x
– volume: 19
  start-page: 1654
  year: 2017
  ident: R72-20231004
  article-title: RUNX1-ETO and RUNX1-EVI1 differentially reprogram the chromatin landscape in t (8; 21) and t (3; 21) AML.
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2017.05.005
– volume: 9
  start-page: 1
  year: 2009
  ident: R44-20231004
  article-title: Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-9-368
– volume: 24
  start-page: 81
  year: 2010
  ident: R59-20231004
  article-title: EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization.
  publication-title: Leukemia
  doi: 10.1038/leu.2009.202
– volume: 136
  start-page: 224
  year: 2020
  ident: R85-20231004
  article-title: Atypical 3q26/MECOM rearrangements genocopy inv (3)/t (3; 3) in acute myeloid leukemia.
  publication-title: Blood
  doi: 10.1182/blood.2019003701
– volume: 127
  start-page: 2391
  year: 2016
  ident: R28-20231004
  article-title: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
  publication-title: Blood
  doi: 10.1182/blood-2016-03-643544
– volume: 6
  start-page: e20793
  year: 2011
  ident: R60-20231004
  article-title: The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA.
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0020793
– volume: 7
  start-page: 1577
  year: 2023
  ident: R51-20231004
  article-title: EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2022008018
– volume: 96
  start-page: 1448
  year: 2011
  ident: R27-20231004
  article-title: Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
  publication-title: Haematologica
  doi: 10.3324/haematol.2011.040535
– volume: 162
  start-page: 670
  year: 2013
  ident: R29-20231004
  article-title: High EVI 1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children’s oncology group.
  publication-title: Br J Haematol
  doi: 10.1111/bjh.12444
– volume: 117
  start-page: e161
  year: 2011
  ident: R95-20231004
  article-title: Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.
  publication-title: Blood
  doi: 10.1182/blood-2010-09-308726
– volume: 11
  start-page: 352
  year: 1997
  ident: R4-20231004
  article-title: The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2400584
– volume: 133
  start-page: 92
  year: 2010
  ident: R96-20231004
  article-title: Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with Fanconi anemia: morphologic and cytogenetic characteristics.
  publication-title: Am J Clin Pathol
  doi: 10.1309/AJCP7W9VMJENZOVG
– volume: 67
  start-page: 3074
  year: 2007
  ident: R43-20231004
  article-title: Amplification of MDS1/EVI1 and EVI1, located in the 3q26. 2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-2366
– volume: 20
  start-page: 48
  year: 2006
  ident: R93-20231004
  article-title: Characterization of a recurrent translocation t (2; 3)(p15–22; q26) occurring in acute myeloid leukaemia.
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404020
– volume: 65
  start-page: 55
  year: 1997
  ident: R11-20231004
  article-title: The Evil proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development.
  publication-title: Mech Dev
  doi: 10.1016/S0925-4773(97)00057-9
– volume: 2
  start-page: 586
  year: 2018
  ident: R20-20231004
  article-title: MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia.
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2018016501
– volume: 23
  start-page: 301
  year: 2017
  ident: R116-20231004
  article-title: The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
  publication-title: Nat Med
  doi: 10.1038/nm.4283
– volume: 131
  start-page: 717
  year: 2018
  ident: R22-20231004
  article-title: A landscape of germ line mutations in a cohort of inherited bone marrow failure patients.
  publication-title: Blood
  doi: 10.1182/blood-2017-09-806489
– volume: 76
  start-page: 2594
  year: 1990
  ident: R70-20231004
  article-title: t (3; 21)(q26; q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia.
  publication-title: Blood
  doi: 10.1182/blood.V76.12.2594.2594
– volume: 327
  start-page: 1650
  year: 2010
  ident: R105-20231004
  article-title: The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML.
  publication-title: Science
  doi: 10.1126/science.1186624
– volume: 11
  start-page: 1
  year: 2020
  ident: R10-20231004
  article-title: EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal.
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-020-03099-0
– volume: 153
  start-page: 307
  year: 2013
  ident: R111-20231004
  article-title: Master transcription factors and mediator establish super-enhancers at key cell identity genes.
  publication-title: Cell
  doi: 10.1016/j.cell.2013.03.035
– volume: 3
  start-page: 207
  year: 2008
  ident: R18-20231004
  article-title: Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells.
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2008.06.002
– volume: 2
  start-page: 143
  year: 2013
  ident: R107-20231004
  article-title: Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.
  publication-title: Stem Cells Transl Med
  doi: 10.5966/sctm.2012-0109
– volume: 27
  start-page: 852
  year: 2013
  ident: R106-20231004
  article-title: Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
  publication-title: Leukemia
  doi: 10.1038/leu.2012.363
– volume: 101
  start-page: 837
  year: 2003
  ident: R31-20231004
  article-title: High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
  publication-title: Blood
  doi: 10.1182/blood-2002-05-1459
– volume: 54
  start-page: 831
  year: 1988
  ident: R101-20231004
  article-title: Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines.
  publication-title: Cell
  doi: 10.1016/S0092-8674(88)91175-0
– volume: 24
  start-page: 1976
  year: 2005
  ident: R13-20231004
  article-title: Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.
  publication-title: EMBO J
  doi: 10.1038/sj.emboj.7600679
– volume: 10
  start-page: 788
  year: 1996
  ident: R37-20231004
  article-title: Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia.
  publication-title: Leukemia
– volume: 208
  start-page: 2403
  year: 2011
  ident: R14-20231004
  article-title: Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity.
  publication-title: J Exp Med
  doi: 10.1084/jem.20110447
– volume: 24
  start-page: 69
  year: 2023
  ident: R19-20231004
  article-title: A genetic disorder reveals a hematopoietic stem cell regulatory network co-opted in leukemia.
  publication-title: Nat Immunol
  doi: 10.1038/s41590-022-01370-4
– volume: 130
  start-page: 908
  year: 2017
  ident: R79-20231004
  article-title: GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
  publication-title: Blood
  doi: 10.1182/blood-2016-12-756767
– volume: 10
  start-page: 1961
  year: 1995
  ident: R3-20231004
  article-title: EVI-1 zinc finger protein works as a transcriptional activator via binding to a consensus sequence of GACAAGATAAGATAAN1-28 CTCATCTTC.
  publication-title: Oncogene
– volume: 97
  start-page: 848
  year: 2015
  ident: R21-20231004
  article-title: Mutations in MECOM, encoding oncoprotein EVI1, cause radioulnar synostosis with amegakaryocytic thrombocytopenia.
  publication-title: Am J Hum Genet
  doi: 10.1016/j.ajhg.2015.10.010
– volume: 43
  start-page: 1012
  year: 2011
  ident: R80-20231004
  article-title: Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.
  publication-title: Nat Genet
  doi: 10.1038/ng.913
– volume: 91
  start-page: 1221
  year: 2012
  ident: R36-20231004
  article-title: Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
  publication-title: Ann Hematol
  doi: 10.1007/s00277-012-1457-7
– volume: 27
  start-page: 1127
  year: 2013
  ident: R23-20231004
  article-title: Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells.
  publication-title: Leukemia
  doi: 10.1038/leu.2012.355
– volume: 28
  start-page: 3890
  year: 2010
  ident: R32-20231004
  article-title: Clinical, molecular, and prognostic significance of WHO type inv (3)(q21q26. 2)/t (3; 3)(q21; q26. 2) and various other 3q abnormalities in acute myeloid leukemia.
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.29.2771
– volume: 24
  start-page: 942
  year: 2010
  ident: R33-20231004
  article-title: EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
  publication-title: Leukemia
  doi: 10.1038/leu.2010.47
– volume: 117
  start-page: 3617
  year: 2011
  ident: R54-20231004
  article-title: Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
  publication-title: Blood
  doi: 10.1182/blood-2009-12-261602
– volume: 140
  start-page: 1200
  year: 2022
  ident: R75-20231004
  article-title: International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
  publication-title: Blood
  doi: 10.1182/blood.2022015850
– volume: 122
  start-page: e12
  year: 2013
  ident: R84-20231004
  article-title: Genome-wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected network of coding and noncoding genes.
  publication-title: Blood
  doi: 10.1182/blood-2013-03-490425
– volume: 36
  start-page: 2927
  year: 2022
  ident: R81-20231004
  article-title: SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase.
  publication-title: Leukemia
  doi: 10.1038/s41375-022-01734-7
– volume: 57
  start-page: 564
  year: 1997
  ident: R74-20231004
  article-title: Fusion of ETV6 to MDS1/EVI1 as a result of t (3; 12)(q26; p13) in myeloproliferative disorders.
  publication-title: Cancer Res
SSID ssj0001999627
Score 2.2716055
SecondaryResourceType review_article
Snippet Ecotropic viral integration site 1 (EVI1), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and...
Ecotropic viral integration site 1 (EVI1 ), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and...
SourceID doaj
pubmedcentral
proquest
crossref
wolterskluwer
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage e959
SubjectTerms Review
SummonAdditionalLinks – databaseName: Wiley Online Library Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZKuXBBVIAIBRQkrlHj2I6dY1vtKq20VSUo6s3yb6koSdVtxZVH4Bl5ks44my2pKkDkFPknVuwZz2d75jMhH5AihFFhQdNEKLiMtMDDpIIZY5Qxoaw8Bgovjur2hB-eitMNMh9jYQZ-iPWGG2pGmq9RwY1d7tyRx7Yfm4F8cHwa0TwijwHfM5T0ih_f7bUgqk-3t4KAVgUsOegYRdfInYc-NLFSicx_gkDv-08OuBbSv_d4xr38mlzcfzNU82fk6Qph5ruDSGyRjdA9J7uzzwf014-fKVAEQGZ-PPhlfQPLlfcxP0LoepGbzucLQOZn6B6Tt8jn2l_2sJg-X74gJ_PZp_22WN2eUDgBy4QignFylnJqmQs8CFlGGZUyLjpkgaOeKlexoMBa2dIaXzswTAEyY8W9VZa9JJtd34VXJJcAc7jiDWfOIf2MAdXy8FqrKIwwISNs7C3tVtTieMPFhR6PuKGP9f0-zkixrnU5UGv8pfweDsS6LBJjp4T-6kyv9EzL4ETk1kvpObcS5peytLX1NrAUdZyR9-MwalAkPB0xXehvlhqJ_xWreV1lRE3Gd9LiNKc7_5IoufGaUQamPiN1EoV_-iHdzhZsD4k9JFSkE9nRQxjsH-u__t_GtsmTCrDa4JP4hmxeX92Et4Ctru27pDi3kqQTAw
  priority: 102
  providerName: Wiley-Blackwell
Title EVI1‐mediated Programming of Normal and Malignant Hematopoiesis
URI https://onlinelibrary.wiley.com/doi/abs/10.1097%2FHS9.0000000000000959
https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&DO=10.1097/HS9.0000000000000959
https://www.proquest.com/docview/2874836462
https://pubmed.ncbi.nlm.nih.gov/PMC10553128
https://doaj.org/article/7ec5f4bd77d44b719600b6bdbe305334
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwELVauHCpWkFFCqxSqdeIJHZi54QKDUqRliK1IG6WPykqTRAL6t_vjL1BGw7QQ3OKYltJxjOZ58zMMyGfkCKEFpUGS6tcxrgvMgwmZVQpJZRyeWmxUHh-Wnfn7OSyulzZ6gtzwiI9cBTcPnem8kxbzi1jmoPC5LmutdWOhjJS_PrmTb6ymAp_VxDHl3yslWv4fve9iVyF49EgPemKLwqU_ROc-TRLMqJXuP5nwEj24ldIZF9xR8dvyZsljkw_x-d_R165fpMctBdfiywUgwCQTM9i7tVv8E7p4NNThKc3qeptOgf0fYUpMGmHnK3D7QAL5uvFFjk_bn8cddlyh4TMVLAUyDw4IKMLVmhqHHMVzz33QijjDTK9FbYQpqROgEfSuVa2NuB8HDT6klktNH1P1vqhd9sk5QBlmGANo8YgxYwC87FwWgtfqUq5hNBRVtIs6cNxF4sbOYaxQcLyqYQTkj2Ouo30GS_0P8RpeOyL5NfhAqiEXKqEfEklEvJxnEQJxoIRENW74WEhkdxf0JrVZULEZHYnd5y29Nc_A-02biVKwZ0npA6K8E8vJLt2Tg-RvIPDwGKiOTKWuj47_sP_EMgO2SgBm8UcxF2ydn_34PYAS93rGXldsrNZMJ4ZWf920bZf_gL--hYP
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKe4ALAgEiPIOE9haUxE7sPUSo3aakpbuttNtSTpbt2KVQklW3hb_PTB6FVOIhckmUeBTF9ng-Z2a-IeQ1UoTQKNGgaYkNGHdRgM6kgCqlhFI2jEtMFJ7O0uKI7Z0kJ2vkc58Lg9lnq-UbPDXrNF5gPRzcGC6yvfloln-YZ9VoMp9kH0eHm-_y5j81RkmMtrP6m4PTQdZTMxbzcUtQ2B_jZHyLbKQAW0ADNg6O83z75x8ZxP4x7_PrfiM-sF8Nzf8Am96MrGwRL9z_XqP3e_WlCX7_xYTt3CN3O-zpb7aT5T5Zs9UD8jY_3o2CJoEEwKd_2MZrfQWL5tfOnyGkPfdVVfpTQOynGDbjF8jzWi9r2GSfrR6So518MSmCrqpCYBLYPgQOjJbREYs0NZbZhIeOOyGUcQbZ4aIyEiamVoAV06FWZWrAYFl46GJWaqHpI7Je1ZV9THwO8IcJNmbUGKSlUaByJVymwiUqUdYjtO8raTrKcax8cS571zf0sLzZwx4JrqWWLeXGX9pv4TBct0XC7OZGfXEqO_2T3JrEMV1yXjKmOaw7YahTXWpLm2xkj7zqB1GCgqHXRFW2vlpJLAggaMrS2CNiMLqDNw6fVGefGqpuLD9KAQJ4JG0mwj99kCzyKd1Cwg8OgtFg5sg2PfaP8k_-Q-YluV0spvtyf3f2_im5EwOUa0MWn5H1y4sr-xyg16V-0enMD0vpHwc
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db5RAEN_Ua2J8MRo1Ur8wMbxhgF1g74GY9o6TVo9ecm2tT5vdZamNFS69q8b_3hk-qjTxI_LCBpgQdnd2fsPO_IaQV0gRQv1QgaaFxmVx6bu4meRSKSWX0nhBgYnC8zzKjtnBaXi6RfrQIUw-W69e46lZprGB5XDQLzxKDpbOZDlJPjp5-mGZ5M5i923a_KbGIAlnMZ0l351pUn8tN870MOn5GbPluGUp7I9xOL5FtjlgDTYi24cnaTr9-VsGHYAg7pPsfiM-MGIN1_8AoN4Mr2xhL1z_VuMW-PpzEwH_ix2b3SN3OwBq77Yz5j7ZMtUD8iY92ffdJosEEKi9aIO2voBZs-vSzhHXXtiyKuw5wPYzjJ2xMyR7rVc1eNrn64fkeJYeTTK3K63g6hB8CLcEy6WVz3xFtWEmjL0yLjmXutRIEecXPtcBNRxMmfKULCINVsvAzTJgheKKPiKjqq7MY2LHgIEYZ2NGtUZuGgl6V0Az4mUoQ2ksQvu-ErrjHcfyFxei3_-GHhY3e9gi7rXUquXd-MvzezgM188ia3Zzob48E50SitjosGSqiOOCMRXD4uN5KlKFMrRJSbbIy34QBWgZbp3IytRXa4FVATiNWBRYhA9Gd_DG4Z3q_FPD1401SCngAItEzUT4pw8SWTqne8j6EYOgP5g5os2R_aP8zn_IvCC3QYnE-_383RNyJwA414YtPiWjzeWVeQbwa6OedyrzA7n3H88
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EVI1-mediated+Programming+of+Normal+and+Malignant+Hematopoiesis&rft.jtitle=HemaSphere&rft.au=Lux%2C+Susanne&rft.au=Milsom%2C+Michael+D.&rft.date=2023-10-01&rft.pub=Lippincott+Williams+%26+Wilkins&rft.eissn=2572-9241&rft.volume=7&rft.issue=10&rft.spage=e959&rft_id=info:doi/10.1097%2FHS9.0000000000000959&rft.externalDBID=NO_PDF_LINK&rft.externalDocID=HemaSphere-2022-0073
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2572-9241&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2572-9241&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2572-9241&client=summon